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ABBREVIATIONS 
ACE =       Angiotensin -Converting Enzyme 
BP    =       British Pharmacopoeia 
cm                                           =       Centimeter 
Conc. = Concentration 
cps =       Centipoises 
CRDDS                                   =       Controlled Release Drug Delivery System 
°C =  Degree Centigrade 
EC =        Ethylcellulose 
F =  Formulation 
FTIR  =        Fourier Transform Infrared Spectroscopy 
g                                              =        Gram 
GIT                                         =        Gastrointestinal tract 
h =  Hour 
HCl =  Hydrochloric acid 
HPMC = Hydroxypropylmethylcellulose 
IP                                             =       Indian Pharmacopoeia 
IPA                                          =       Isopropyl alcohol 
ISA =        Intrinsic sympathomimetic activity 
Kg =       Kilogram 
LD                                           =       Lethal Dose 
LR = Laboratory Reagent 
MCC =       Microcrystalline cellulose 
mcg =  Microgram 
MDT                                        = Mean dissolution time 
MEC                                        =      Minimum Effective Concentration 
mg = Milligram 
min = Minute 
mL = Milliliter 
mPa s =      Milli Pascal Second 
MS                                          =      Magnesium Stearate 
MSC                                       =       Maximum Safe Concentration 
n = Diffusion coefficient 
N =   Normality 
NaCl                                        =        Sodium Chloride 
nm =   Nanometer 
NMR =        Nuclear Magnetic Resonance 
No.                                          =        Number 
PEO =        Polyethylene Oxide 
PVP =        Polyvinylpyrrolidone 
RH =        Relative Humidity 
rpm =  Revolutions per minute 
SD                                           =        Standard Deviation 
S. No. =  Serial Number 
SR =        Sustained-Release 
TM                                          =        Timolol Maleate 
USP =  United States Pharmacopoeia 
UV =  Ultraviolet 
w/w =  Weight by weight 
μm =        Micrometer 
% =  Percentage 
β =        Beta 
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INTRODUCTION 
           Most conventional oral drug products, such as tablets and capsules, are formulated to release 
the active drug immediately after oral administration, to obtain rapid and complete systemic drug 
absorption. Such immediate-release products result in relatively rapid drug absorption and onset of 
accompanying pharmacodynamic effects. However, after absorption of the drug from the dosage form 
is complete, plasma drug concentrations decline according to the drug's pharmacokinetic profile. 
Eventually, plasma drug concentrations fall below the minimum effective plasma concentration 
(MEC), resulting in loss of therapeutic activity. Before this point is reached, another dose is usually 
given if a sustained therapeutic effect is desired. An alternative to administering another dose is to use 
a dosage form that will provide sustained drug release, and therefore maintain plasma drug 
concentrations, beyond what is typically seen using immediate-release dosage forms. In recent years, 
various modified-release drug products have been developed to control the release rate of the drug 
and/or the time for drug release.  
             The term modified-release drug product is used to describe products that alter the timing 
and/or the rate of release of the drug substance. A modified-release dosage form is defined "as one for 
which the drug-release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms such as solutions, 
ointments, or promptly dissolving dosage forms as presently recognized". Several types of modified-
release drug products are recognized (Leon Shargel et al., 2004). 
Extended-release drug products: A dosage form that allows at least a twofold reduction in dosage 
frequency as compared to that drug presented as an immediate-release (conventional) dosage form. 
Examples of extended-release dosage forms include controlled-release, sustained-release, and long-
acting drug products.  
Delayed-release drug products: A dosage form that releases a discrete portion or portions of drug at a 
time or at times other than promptly after administration, although one portion may be released 
promptly after administration. Enteric-coated dosage forms are the most common delayed-release 
products.  
Targeted-release drug products: A dosage form that releases drug at or near the intended physiologic 
site of action. Targeted-release dosage forms may have either immediate- or extended-release 
characteristics. 
The term controlled-release drug product was previously used to describe various types of 
oral extended-release-rate dosage forms, including sustained-release, sustained-action, prolonged-
action, long-action, slow-release, and programmed drug delivery.  
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Conventional Drug Delivery System 
Pharmaceutical products designed for oral delivery are mainly conventional drug delivery 
systems, which are designed for immediate release of drug for rapid/immediate absorption (Robinson, 
1987). 
           As can be seen in the graph (Figure 1), administration of the conventional dosage form by extra 
vascular route does not maintain the drug level in blood for an extended period of time. The short 
duration of action is due to the inability of conventional dosage form to control temporal delivery.  
 
Fig. 1.   A hypothetical plasma concentration-time profile from conventional multiple dosing and 
single doses of sustained and controlled delivery formulations. (MSC = maximum safe concentration, 
MEC = minimum effective concentration). 
The conventional dosage forms like solution, suspension, capsule, tablets and suppository etc, 
have some limitations such as, 
1) Drugs with short half-life require frequent administration, which increases chances of missing the 
dose of drug leading to poor patient compliance. 
2) A typical peak-valley plasma concentration-time profile is obtained which makes attainment of 
steady state condition difficult. The unavoidable fluctuations in the drug concentration may lead 
to under medication or overmedication as the steady state concentration values fall or rise beyond 
the therapeutic range.  
3) The fluctuating drug levels may lead to precipitation of adverse effects especially of a drug with 
small therapeutic index, whenever overdosing occurs.  
In order to overcome the drawbacks of conventional drug delivery systems, several technical 
advancements have led to the development of controlled drug delivery system that could revolutionize 
method of medication and provide a number of therapeutic benefits (Chien, 1992). 
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Controlled Release Drug Delivery Systems (CRDDS) 
      More precisely, controlled delivery can be defined as, 
1) Sustained drug action at a predetermined rate by maintaining a relatively constant, effective drug 
level in the body with concomitant minimization of undesirable side effects. 
2) Localized drug action by spatial placement of a controlled release system adjacent to or in the 
diseased tissue.  
3) Targeted drug action by using carriers or chemical derivatives to deliver drug to a particular target 
cell type.  
4) Provide a physiologically / therapeutically based drug release system. In other words, the amount 
and the rate of drug release are determined by the physiological/ therapeutic needs of the body.  
A controlled drug delivery system is usually designed to deliver the drug at particular rate. 
Safe and effective blood levels are maintained for a period as long as the system continues to deliver 
the drug. This predetermined rate of drug release is based on the desired therapeutic concentration and 
the drug’s pharmacokinetics.  
Advantages of Controlled Drug Delivery System  
1. Overcome patient compliance problems.  
2. Employ less total drug,  
a) Minimize or eliminate local side effects. 
b) Minimize or eliminate systemic side effects.  
c) Obtain less potentiation or reduction in drug activity with chronic use. 
d) Minimize drug accumulation with chronic dosing.  
3. Improve efficiency in treatment,  
a) Cures or controls condition more promptly. 
b) Improves control of condition i.e., reduced fluctuation in drug level. 
c) Improves bioavailability of some drugs. 
d) Make use of special effects, e.g. Sustained-release aspirin for morning relief of arthritis by 
dosing before bed time.  
4. Economy i.e. reduction in health care costs. The average cost of treatment over an extended time 
period may be less, with lesser frequency of dosing, enhanced therapeutic benefits and reduced 
side effects. The time required for health care personnel to dispense and administer the drug and 
monitor patient is also reduced.  
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Disadvantages 
1) Decreased systemic availability in comparison to immediate release conventional dosage forms, 
which may be due to incomplete release, increased first-pass metabolism, increased instability, 
insufficient residence time for complete release, site specific absorption, pH dependent stability 
etc.  
2) Poor in vitro – in vivo correlation.  
3) Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity reactions.  
4) Reduced potential for dose adjustment of drugs normally administered in varying strengths 
(Hoffman, 1998). 
Oral Controlled Drug Delivery Systems  
Oral controlled release drug delivery is a system that provides continuous oral delivery of 
drugs at predictable and reproducible kinetics for a predetermined period throughout the course of GI 
transit and also the system that target the delivery of a drug to a specific region within the GI tract for 
either a local or systemic action (Vora et al., 1996). 
Classification of Oral Controlled Release Systems  
A) Diffusion Controlled Systems 
I.  Reservoir Devices. 
A core of drug (the reservoir) surrounded by a polymeric membrane characterizes them. The 
nature of the membrane determines the rate of drug release. 
The characteristics of reservoir diffusion systems are, 
1. Zero order drug release is possible. 
2. The drug release rate is dependent on the type of polymer. 
3. High molecular weight compounds are difficult to deliver through the device. Coating and 
microencapsulation technique can be used to prepare sub devices. 
II.  Matrix Devices. 
  It consists of drug dispersed homogeneously in a matrix. The characteristics of the matrix 
diffusion systems are, 
1. Zero order release cannot be obtained. 
2. Easy to produce than reservoir devices. 
3. High molecule weight compounds are delivered through the devices. 
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B) Dissolution controlled systems 
I. Matrix Dissolution Controlled System 
 Aqueous dispersions, congealing, spherical agglomeration etc. can be used.   
II.    Encapsulation Dissolution Control 
  Particles, seeds or granules can be coated by technique such as microencapsulation. 
C) Diffusion and Dissolution Controlled System. 
       In a bioerodible matrix, the drug is homogenously dispersed in a matrix and it is released 
either by swelling controlled mechanism or by hydrolysis or by enzymatic attack. 
Types of Extended-Release Products 
 General approaches to manufacturing an extended-release drug product include the use of a 
matrix structure in which the drug is suspended or dissolved, the use of a rate-controlling membrane 
through which the drug diffuses, or a combination of both. Among the many types of commercial 
preparations available, none works by a single drug-release mechanism. Most extended-release 
products release drug by a combination of processes involving dissolution, permeation, and diffusion. 
The single most important factor is water permeation, without which none of the product release 
mechanisms would operate. Controlling the rate of water influx into the product generally dictates the 
rate at which the drug dissolves. Once the drug is dissolved, the rate of drug diffusion may be further 
controlled to a desirable rate. Table 1 shows some common extended-release product examples and 
the mechanisms for controlling drug release, and lists the compositions for some drugs (Leon Shargel, 
2004).                                        
Table 1.  Examples of Oral Extended-Release Products 
Type Trade Name Rationale 
Erosion tablet 
  
  
Constant-T Theophylline  
Tenuate Dospan Diethylpropion HCl dispersed in hydrophilic matrix 
Tedral SA Combination product with a slow-erosion 
component (theophylline, ephedrine HCl) and an 
initial-release component theophylline, ephedrine 
HCl, phenobarbital) 
Waxy matrix tablet Kaon Cl   Slow release of potassium chloride to reduce GI 
irritation 
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Coated pellets in 
capsule 
Ornade spansule Combination phenylpropanolamine HCl and 
chlorpheniramine with initial- and extended-release 
component 
Pellets in tablet Theo-Dur Theophylline  
Leaching 
  
Ferro-Gradumet 
(Abbott) 
Ferrous sulfate in a porous plastic matrix that is 
excreted in the stool; slow release of iron decreases 
GI irritation 
Desoxyn gradumet 
tablet (Abbott) 
Methamphetamine methylacrylate 
methylmethacrylate copolymer, povidone, 
magnesium stearate; the plastic matrix is porous 
Coated ion exchange Tussionex Cation ion-exchange resin complex of hydrocodone 
and phenyltoloxamine 
Flotation–diffusion Valrelease Diazapam 
Osmotic delivery 
  
Acutrim Phenylpropanolamine HCl (Oros delivery system) 
Procardia-XL GITS—gastrointestinal therapeutic system with 
NaCl-driven (osmotic pressure) delivery system for 
nifedipine  
Microencapsulation 
  
  
Bayer timed-release Aspirin 
Nitrospan Microencapsulated nitroglycerin  
Micro-K Extencaps Potassium chloride microencapsulated particles 
 
Factors Influencing the Design and Performance of Sustained Release Products 
          The type of delivery system and route of administration of the drug presented in sustained drug 
delivery system may depend upon two properties (Bramhankar and Jaiswal, 1995). They are, 
I. Physicochemical Properties of drugs. 
II. Biological Factors. 
I. Physicochemical Properties of Drugs 
1. Dose size  
For orally administered systems, there is an upper limit to the bulk size of the dose to be 
administered. In general a single dose of 0.5 to 1gm is considered maximum (Nicholas et al., 1987). 
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2. Ionization, PKa & Aqueous Solubility  
               The pH Partition hypothesis simply states that the unchanged form of a drug species will be 
preferentially absorbed through many body tissues. Therefore it is important to note the relationship 
between the PKa of the compound and its absorptive environment. For many compounds, the site of 
maximum absorption will also be the area in which the drug is least soluble. 
                   For conventional dosage forms the drug can generally fully dissolve in the stomach and then 
be absorbed in the alkaline pH of the intestine. For sustained release formulations much of the drug 
will arrive in the small intestine in solid form. This means that the solubility of the drug is likely to 
change several orders of magnitude during its release. 
 Compounds with very low solubility are inherently controlled, since their release over the 
time course of a dosage form in the GIT will be limited by dissolution of the drug. The lower limit for 
the solubility of a drug to be formulated in a sustained release system has been reported to be 
0.1mg/mL (Fincher et al., 1968). Thus for slightly soluble drugs, diffusional systems will be poor 
choice, since the concentration in solution will be low.            
  For example Tetracycline has maximum solubility in the stomach and least     solubility in the 
intestine where it is maximally absorbed. Other examples of drugs whose incorporation into sustained 
release systems are limited because of their poor aqueous solubility and slow dissolution rate are 
digoxin, warfarrin, griseofulvin and salicylamide. Very soluble drugs are also good candidates for the 
sustained release dosage forms.  
3. Partition coefficient     
            The compounds with a relatively high partition coefficient are predominantly lipid soluble and 
easily penetrate membranes resulting high bioavailability. Compounds with very low partition 
coefficient will have difficulty in penetrating membranes resulting poor bioavailability. Furthermore 
partitioning effects apply equally to diffusion through polymer membranes. 
4. Drug Stability 
               The drugs, which are unstable in stomach, can be placed in a slowly soluble form and their 
release delayed until they reach the small intestine. However, such a strategy would be detrimental for 
drugs that either are unstable in the small intestine (or) undergo extensive gut wall metabolism, as 
pointed out in the decrease bioavailability of some anticholinergic drugs from controlled /sustained 
release formulation. In general the drugs, which are unstable in GIT environment poor candidates for 
oral sustained release forms. 
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5. Protein Binding  
       It is well known that many drugs bind to plasma proteins with a concomitant influence on the 
duration of drug action. Since blood proteins are mostly recirculated and not eliminated. Drug protein 
binding can serve as depot for drug producing a prolonged release profile, especially if a high degree 
of drug binding occurs. 
II. Biological Factors 
1. Biological Half-Life 
Therapeutic compounds with half-life less than 8 hrs are excellent candidates for sustained 
release preparations. Drugs with very short half-life (less than 2 hrs) will require excessively large 
amounts of drug in each dosage unit to maintain controlled effects. Thus forcing the dosage form 
itself to become too large to be administered. Compounds with relatively long half-lives, generally 
greater than 8 hrs are not used in the sustained release dosage forms, since their effect is already 
sustained and also GI transit time is 8-12 hrs (Jantzen et al., 1996). So the drugs, which have long -
half life and short half- life, are poor candidates for sustained release dosage forms. 
Some examples of drug with half-lives of less than 2 hours are ampicillin, cephalexin, 
cloxacillin, furosemide, levodopa, penicillin G and propylthiouracil. Examples of those with half-lives 
of greater than 8 hours are dicumarol, diazepam, digitoxin, digoxin, guanethidine, phenytoin and 
warfarin. 
2. Absorption 
The characteristics of absorption of a drug can greatly affect its suitability as a sustained 
release product. Drugs which are absorbed by specialized transport process (carrier mediated) and 
drug absorption at special sites of the gastrointestinal tract (Absorption Window) are poor candidates 
for sustained release products. 
3. Metabolism 
  The metabolic conversion of a drug to another chemical form usually can be considered in 
the design of a sustained-release system for that drug. As long as the location, rate and extent of 
metabolism are known and the rate constant(s) for the process (es) are not too large, successful 
sustained-release products can be developed.          
  There are two factors associated with the metabolism of some drugs; however that present 
problems of their use in sustained-release systems. One is the ability of the drug to induce or inhibit 
enzyme synthesis; this may result in a fluctuating drug blood level with chronic dosing. The other is a 
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fluctuating drug blood level due to intestinal (or other tissue) metabolism or through a hepatic first-
pass effect. 
    Examples of drugs that are subject to intestinal metabolism upon oral dosing are 
hydralazine, salicylamide, nitroglycerine, isoproterenol, chlorpromazine and levodopa. Examples of 
drugs that undergo extensive first-pass hepatic metabolism are propoxyphene, nortriptyline, 
phenacetine, propranolol and lidocaine. 
           Drugs that are significantly metabolized especially in the region of the small intestine can show 
decreased bioavailability from slower releasing dosage forms. This is due to saturation of intestinal 
wall enzyme systems. The drugs should not have intestinal first pass effect and should not induce (or) 
inhibit metabolism are good candidates for sustained release dosage forms. Various technologies used 
for controlled release drug delivery systems were given in Table 2 (Chien et al., 1990). 
Table 2. Technologies used for CRDDS  
S.NO. DESIGN OR TYPE OF THE SYSTEM    RELEASE     MECHANISM 
1 Dissolution  CR systems 
• Encapsulation (including   
Microencapsulation) 
       - Barrier coating 
       - Embedment into a matrix of fatty 
materials)                                     
       - Repeat action coatings 
       - Coated plastic materials or hydrophilic 
materials 
• Matrix Dissolution Control  
The dissolution of drug from system 
2 Diffusion CR systems 
• Reservoir Devices  
• Matrix Devices        
The diffusion of the drug solution through 
a water  
 
3 Dissolution and Diffusion  CR systems  
• Non disintegrating polymeric matrix 
• Hydrophilic matrices  
Diffusion of a drug solution through a 
porous matrix 
 
4 Ion- Exchange Resin CR Systems Ion- Exchange between the resin - drug 
complex and  ions in the GI tract 
5 pH - Independent formulations 
 
Influenced by change in pH and ionic 
permeability of the membrane coating 
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6 Osmotically CR systems 
They contain the buffering agents in a 
system which maintains constant pH 
throughout the GIT, so the drug release 
from the device is not affected by variable 
pH of GIT. Water entering by Osmosis 
dissolves the drug,  and the drug solution 
is forced out through a laser drilled orifice 
7 Altered - Density systems Diffusion from high - density pellets or 
from floating 
 
Monolithic Matrix System  
           In pharmaceutical CRDDS, matrix based systems are the most commonly used type of release 
controlling methodology owing to their simple manufacturing process. The preparation of a tablet 
with the matrix involves the direct compression of the blends of drug, release retardant and other 
additives, in which the drug is uniformly distribute throughout the matrix core of the release retardant. 
Alternatively, drug-release retardant blends may be granulated to make the mix suitable for the 
preparation of tablets by wet granulation or beads (Colombo et al., 1995). 
  To characterize and define the matrix systems the following properties of the matrix are considered. 
1. Chemical nature of the support. 
2. The physical state of the drug. 
3. The matrix and alteration in volume as the function of the time. 
4. The routes of administration. 
5. The release kinetics model (in accordance with Higuchi’s equation, these system considered 
to release the drug as a function of square root of time).   
The classification of the matrix-based systems is based on the following criteria. 
• Matrix structure. 
• Release kinetics. 
• Controlled release properties (diffusion, erosion and swelling). 
• Chemical nature and the properties of the applied release retardant(s).  
Based on the chemical nature of the release retardant(s), the matrix systems are classified as given in 
Table 3.Table 3. Classification of Matrix Systems. 
Type of the Matrix System Mechanism 
Hydrophilic - Unlimited swelling delivery by diffusion 
- Limited swelling controlled delivery 
eg: Hydroxyethylcellulose, Hydroxypropylmethyl cellulose 
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Inert - Inert in nature 
- Controlled delivery by diffusion 
eg: Ethylcellulose 
Lipidic - Delivery by diffusion & erosion 
eg: Carnauba wax. 
Biodegradable - Non lipidic nature 
- Controlled delivery by surface erosion 
Resin Matrices - Drug release from drug-resin complex 
eg: Ion exchange resins 
 
Mechanism of Drug Release from Matrix Tablets 
 As shown in Figure 2, in erodible matrices, polymer erosion from the surface of the matrix 
determines the drug release; whilst in hydrophilic matrices, formation of the gel layer and its 
dynamics as a function of time determines the drug release. Gel layer thickness, which determines the 
diffusion path length of the drug, corresponds to the distance between the diffusion and erosion fronts. 
As the swelling process proceeds, the gel layer gradually becomes thicker, resulting in progressively 
slower drug-release rates; however, due to continuous hydration, polymer disentanglement occurs 
from the surface of the matrix, resulting in a gradually decreasing depletion zone and an increased 
dissolution rate. 
 
 
Fig.2. Schematic drug release from matrix diffusion controlled-release drug delivery systems with the 
drug homogenously dispersed in: (a) an erodible polymer matrix; and (b) a hydrophilic, sellable 
polymer matrix. 
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Drug Release Kinetics -Model Fitting of the Dissolution Data 
             Whenever a new solid dosage form is developed or produced, it is necessary to ensure that 
drug dissolution occurs in an appropriate manner. The pharmaceutical industry and the registration 
authorities do focus, nowadays, on drug dissolution studies. Drug dissolution from solid dosage forms 
has been described by kinetic models in which the dissolved amount of drug (Q) is a function of the 
test time, t or Q=f(t). Some analytical definitions of the Q(t) function are commonly used, such as 
zero order, first order, Hixson–Crowell, Higuchi, Korsmeyer–Peppas  models. (Mulye and Turco, 
1995; Colombo et al., 1999; Kim et al., 1997; Manthena et al., 2004; Desai et al., 1996; Higuchi et al., 
1963).Different models expressing drug release kinetics were given in Table 4.  
Zero order kinetics 
Q1 = Q0 +K0t 
Where Q1 is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the solution 
(most times, Q0=0) and K0 is the zero order release constant.  
ft = K0 t 
where ft = 1-(Wt/W0) and ft represents the fraction of drug dissolved in time t and K0 the apparent 
dissolution rate constant or zero order release constant. In this way, a graphic of the drug-dissolved 
fraction versus time will be linear if the previously established conditions were fulfilled. 
Use: This relation can be used to describe the drug dissolution of several types of modified release 
pharmaceutical dosage forms, as in the case of some transdermal systems, as well as matrix tablets 
with low soluble drugs, coated forms, osmotic systems, etc. The pharmaceutical dosage forms 
following this profile release the same amount of drug by unit of time and it is the ideal method of 
drug release in order to achieve a pharmacological prolonged action.  
 First order kinetics 
 Kinetic equation for the first order release is as follows 
Log Qt = log Q0 + K1t/2.303 
where Qt is the amount of drug released in time t, Q0 is the initial amount of drug in the solution and 
K1 is the first order release constant. In this way a graphic of the decimal logarithm of the released 
amount of drug versus time will be linear.  
The pharmaceutical dosage forms following this dissolution profile, such as those containing water-
soluble drugs in porous matrices, release the drug in a way that is proportional to the amount of drug 
remaining in its interior, in such way, that the amount of drug released by unit of time diminishes. 
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Higuchi model    
                                                        ft = KH t1/2 
 Where KH is the Higuchi dissolution constant treated sometimes in a different manner by different 
authors and theories. Higuchi describes drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms, as in the case of some transdermal systems 
and matrix tablets with water-soluble drugs. 
Hixson–Crowell model 
Hixson and Crowell (1931) recognizing that the particle regular area is proportional to the cubic root 
of its volume derived an equation that can be described in the following manner 
W0 1/3-Wt 1/3 = Kst 
where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the remaining amount 
of drug in the pharmaceutical dosage form at time t and Ks is a constant incorporating the surface–
volume relation. This expression applies to pharmaceutical dosage form such as tablets, where the 
dissolution occurs in planes that are parallel to the drug surface if the tablet dimensions diminish 
proportionally, in such a manner that the initial geometrical form keeps constant all the time.           
           A graphic of the cubic root of the unreleased fraction of drug versus time will be linear if the 
equilibrium conditions are not reached and if the geometrical shape of the pharmaceutical dosage 
form diminishes proportionally over time. This model has been used to describe the release profile 
keeping in mind the diminishing surface of the drug particles during the dissolution. 
 
Mechanism of Drug Release     
                  To find out the drug release mechanism due to swelling (upon hydration) along with 
gradual erosion of the matrix, first 60% drug release data can be fitted in Korsmeyer–Peppas model 
which is often used to describe the drug release behavior from polymeric systems when the 
mechanism is not well-known or when more than one type of release phenomena is involved 
(Korsmeyer et al., 1983). 
                                          Log (Mt / M∞) = Log KKP + n Log t                                                
where, Mt is the amount of drug release at time t, M∞ is the amount of drug release after infinite time, 
KKP is a release rate constant incorporating structural and geometrical characteristics of the tablet, and 
n is the release exponent indicative of the mechanism of drug release. 
 
 
 
 
K . K  C o l l e g e  o f  P h a r m a c y  Page 14 
Table 4.  Drug Release Kinetics 
Kinetic 
Model 
Relation Systems Following the Model 
First order 
 
ln Qt = ln Qo + Kt 
(release is proportional to amount of drug 
remaining) 
Water-soluble drugs in porous 
matrix 
 
Zero order 
 
ft = Kot 
(independent of drug concentration) 
Transdermal systems 
Osmotic systems 
Higuchi 
 
ft = KHt1/2 
(proportional to square root of time) 
Matrix formulations 
 
Hixson-
Crowell 
Wo 1/3 – Wt 1/3 = Kst Erodible isometric matrices 
ft = fraction of dose release at time ‘t’;  
KH, Ko, and Ks = release rate constants characteristic to respective models;  
Qo = the drug amounts remaining to be released at zero hour;  
Qt = the drug amounts remaining to be released at time ‘t’;  
Wo = initial amount of drug present in the matrix;  
Wt = amount of drug released at time ‘t’. 
 
Introduction to Hypertension and Timolol Maleate 
           Blood pressure is the force of blood pushing against blood vessel walls. The heart pumps blood 
into the arteries (blood vessels), which carry the blood throughout the body. High blood pressure, also 
called hypertension, is dangerous because it makes the heart work harder to pump blood to the body 
and it contributes to hardening of the arteries or atherosclerosis and the development of heart failure. 
   Hypertension, also referred to as high blood pressure, HTN or HPN, is a medical condition in 
which the blood pressure is chronically elevated.  
     There are several categories of blood pressure, including 
• Normal: 120/80 mm of Hg. 
• Prehypertension: 120-139/80-89 mm of Hg. 
• Stage 1 hypertension: 140-159/90-99 mm of Hg. 
• Stage 2 hypertension: 160 and above/100 and above. 
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Hypertension can be classified either essential (primary) or secondary.  
Essential hypertension indicates that no specific medical cause can be found to explain a patient's 
condition. Secondary hypertension indicates that the high blood pressure is a result of (i.e., secondary 
to) another condition, such as kidney disease or tumours.  
The mechanisms and causes of hypertension 
The direct mechanisms causing hypertension is one or more of these factors 
• An increased tension in the blood vessel walls. 
• An increased blood volume caused by elevated levels of salt and lipids in the blood holding 
back water. 
• Hardened and inelastic blood vessels caused by arteriosclerosis. 
• The primary causes behind these mechanisms are not fully understood, but these factors 
contribute to causing hypertension. 
• A high consumption of salt. 
• A high fat consumption. 
• Stress at work and in the daily life. 
• Smoking. 
• Over-weight. 
• Lack of exercise. 
• Kidney failure. 
Lifestyle measures to prevent and treat hypertension 
Lifestyle measures shall always be a component of the hypertension treatment. Sometimes such 
measures are enough to cure the condition. Those measures are 
• Reducing salt consumption. 
• Reduction of fat consumption, and especially of saturated fat consumption. 
• Weight reduction. 
• Relaxing and stress reduction techniques, for example meditation and autogenic training. 
• Regular exercise. 
Special food types that reduce the blood pressure 
Research projects suggest that the following food types reduce blood pressure. 
•  Fish oil and fat fish. The working substances seem to be the omega-3 unsaturated fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The effect from fish oil 
seems to cease when the fish oil supplements are stopped. 
• Olive oil, especially olive oil of the quality extra virgin. 
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Natural supplements to help against hypertension 
            Natural supplements to treat hypertension exist. These supplements reduce blood pressure by 
lowering the cholesterol and lipid content in the blood, by preventing oxidation of tissue components 
by free radicals, and by helping damaged blood vessels to heal. Examples of ingredients having these 
effects are vitamin B3, inositol, turmenic extract and gum guggul extract.  
          They may also contain Ingredients giving a direct anti-hypertensive effect, like potassium, 
magnesium, calcium, vitamin C and fatty acids from marine sources. 
Medical treatment of hypertension  
           When lifestyle measures and supplements are not enough to cure the condition, medical 
treatment must be applied. Many different types of drugs are used, alone or in combination with other 
drugs, to treat high blood pressure. The major categories are 
• Angiotensin-converting Enzyme (ACE) Inhibitors: ACE inhibitors work by preventing a 
chemical in the blood, angiotensin I, from being converted into a substance that increases salt 
and water retention in the body. These drugs also make blood vessels relax, which further 
reduces blood pressure.  
• Angiotensin II Receptor Antagonists: These drugs act at a later step in the same process that 
ACE inhibitors affect. Like ACE inhibitors, they lower blood pressure by relaxing blood 
vessels.  
• Beta blockers: Beta blockers affect the body's response to certain nerve impulses. This, in 
turn, decreases the force and rate of the heart's contractions, which lowers blood pressure.  
• Blood Vessel Dilators (Vasodilators): These drugs lower blood pressure by relaxing muscles 
in the blood vessel walls.  
• Calcium Channel Blockers: Drugs in this group slow the movement of calcium into the cells 
of blood vessels. This relaxes the blood vessels and lowers blood pressure.  
• Diuretics: These drugs control blood pressure by eliminating excess salt and water from the 
body.  
• Nerve Blockers: These drugs control nerve impulses along certain nerve pathways. This 
allows blood vessels to relax and lowers blood pressure.  
Beta blockers 
           Beta blockers differ by which receptors are blocked.  
           First generation beta blockers such as propranolol (Inderal, InnoPran), nadolol (Corgard), 
Timolol maleate  (Blocadren), penbutolol sulfate (Levatol), sotalol hydrochloride (Betapace), and 
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pindolol (Visken) are non-selective in nature, meaning that they block both beta1 (β1) and beta2 (β2) 
receptors and will subsequently affect the heart, kidneys, lungs, gastrointestinal tract, liver, uterus, 
vascular smooth muscle, and skeletal muscle and as an effect, could cause reduced cardiac output, 
reduced renal output amongst other actions.  
          Second generation beta blockers such as metoprolol (Lopressor, Toprol XL), acebutolol 
hydrochloride (Sectral), bisoprolol fumarate (Zebeta), esmolol hydrochloride (Brevibloc), betaxolol 
hydrochloride (Kerlone), and acebutolol hydrochloride (Sectral) are selective, as they block only β1 
receptors and as such will affect mostly the heart and cause reduced cardiac output.     
       
           Beta blockers such as pindolol (Visken), penbutolol sulfate (Levatol), and acebutolol 
hydrochloride (Sectral) differ from other beta blockers as they possess intrinsic sympathomimetic 
activity (ISA), which means they mimic the effects of epinephrine and norepinephrine and can cause 
an increase in blood pressure and heart rate. ISA's have smaller effects in reducing resting cardiac 
output and resting heart rate, in comparison to drugs that do not possess ISA. 
            Beta blocker such as propranolol (Inderal, InnoPran), acebutolol hydrochloride (Sectral), and 
betaxolol hydrochloride (Kerlone) possess a quinidine-like or anesthetic-like membrane action, which 
affects cardiac action potential (electrical impulses within the heart that cause contractions).  
            Beta blockers such as labetalol hydrochloride (Trandate, Normodyne) and carvedilol (Coreg) 
have both β- and α1-adrenergic receptors. Blocking the α1-adrenergic receptors in addition to the β 
blocker lowers blood pressure which provides additional vasodilatory action of the arteries.  
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REVIEW OF LITERATURE 
Matrix Formers  
 Avachat and Vikram (2007) have studied the effect of different concentrations of 
hydroxypropylmethylcellulose (HPMC K100CR) on the simultaneous release of both diclofenac 
sodium (DS) and chondroitin sulphate (CS). They revealed that HPMC K 100CR at a concentration of 
40% of the dosage form weight was able to control the simultaneous release of both DS and CS for 
9hours. 
Krishnan et al., (2007) have prepared sustained release tablets of theophylline using 
tamarind seed polysaccharide as release retardant. The release of drug from these matrices was found 
to occur by swelling controlled mechanism obeying first order kinetics. 
             Nair et al., (2007) have made an attempt to formulate a controlled-release matrix tablet 
formulation for alfuzosin hydrochloride by using low viscous hydroxypropylmethylcellulose (HPMC 
K-100 and HPMC 15cps) and its comparison with marketed product. Drug release from the matrix 
tablets was carried out for 12 hr and showed that the release rate was not highly significant with 
different ratios of HPMC K-100 and HPMC15cps. They concluded that the use of low viscous 
hydrophilic polymer of different grades (HPMC K-100 and HPMC 15cps) can control the alfuzosin 
release for a period of 12 hr and were comparable to the marketed product. 
Raslan & Maswadeh (2006) have studied the effect of HPMC (hydrophilic) and glyceryl 
behenate (hydrophobic) polymers on controlled release of anhydrous theophylline matrix tablets and 
studied invitro release characteristics and kinetics of prepared formulations for explaining the release 
pattern from matrix tablets. 
Atul Kuksal et al., (2006) have prepared extended-release matrix tablets of zidovudine using 
hydrophilic eudragit RLPO and RSPO alone and their combination with hydrophobic ethylcellulose 
(EC). The in-vitro drug release study revealed that either eudragit preparation was able to sustain the 
drug release for 6h. Combining eudragit with EC sustained the drug release for 12 h. 
Hamid et al., (2006) have formulated & evaluated a once-daily tablet of cefpodoxime using 
HPMC K4M. They revealed that 35% w/w of HPMC controlled the cefpodoxime proxetil release 
effectively for 24hours. 
Jaleh et al., (2006) have developed sustained-release matrix tablets of highly water-soluble 
tramadol HCl using natural gums like xanthan gum and guar gum alone or in combination with 
HPMC. They concluded that guar gum alnoe cannot efficiently control drug release, and xanthan gum 
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has higher drug retarding ability than guar gum. The combination of each natural gum with HPMC 
leads to a greater retarding effect compared with a mixture of two natural gums.  
Saleh et al., (2005) have studied the effect of different viscosity grades LM (30% w/w), MM 
(40% w/w), HM (50% w/w) of guar gum on the drug release pattern of water-soluble diltiazem 
hydrochloride. They found that high molecular weight (50% w/w) grade guar gum was able to control 
the drug release patterns in-vitro and in-vivo. 
Vidhyadhara et al., (2004) have revealed that the HPMC K4M along with electrolytes can 
be used as aids to controlled delivery in the formulation of water soluble drugs like propranolol HCl 
from tablet matrix. 
Jaber & Naser (2004) have shown that 15% w/w of carbopol or sodium 
carboxymethylcellulose or 35% w/w of HPMC K100M can be useful to sustain the release of lithium 
carbonate from matrix tablet over 8 hours. 
Sandip et al., (2003) have studied the effect of concentration of hydrophilic (HPMC) and 
hydrophobic (hydrogenated castor oil [HCO], EC) on the release rate of tramadol HCl. Tablets 
prepared by combination of hydrophilic and hydrophobic polymers failed to produce the drug release 
beyond 12 h. HCO matrix tablets were found to be best suited for modulating the delivery the highly 
water-soluble drug, tramadol HCl. 
Selim et al., (2003) have done the comparative evaluation of plastic, hydrophobic and 
hydrophilic polymers as matrices for controlled-release drug delivery. They revealed that the drug 
release from plastic and hydrophobic matrix was less than hydrophilic polymer. Again, the release 
pattern of drug from hydrophilic matrices was closer to zero-order kinetics than that from other 
classes of matrices. 
Nath et al., (1999) have discussed the use of combination of aliphatic alcohol (cetyl alcohol) 
and methylcellulose as a sustained release matrix using theophylline as a model drug. They have 
shown that 30% w/w total matrix component gave extended release of theophylline for more than 
8hours. 
Pillay and Fassihi (1999) have studied the interaction between drug and electrolyte(s) to 
control the release of highly water soluble diltiazem hydrochloride from oral hydrophilic monolithic 
systems. They have used hydrophilic polymers like HPMC and PEO. Electrolytes such as sodium 
bicarbonate or pentasodium tripolyphosphate were used to modulate intragel pH dynamics, swelling 
kinetics, and gel properties. They concluded that the dynamics of swelling and gel formation in the 
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presence of ionizable species within hydrophilic matrices provide an attractive alternative for zero-
order drug delivery from a simple monolithic system. 
Bhalla and Handa (1998) have prepared controlled release tablets of carbamazepine using 
HPMC and EC as release retardants and performed in-vitro & in-vivo studies. They found that EC 
based formulation was found to be more stable and compared well with the innovator’s product. 
Kim and Fassihi (1997) have developed a new ternary polymeric matrix system using pectin, 
HPMC and gelatin to deliver a highly soluble drug like diltiazem HCl over long periods of time. They 
mentioned that this system offers a number of advantages over existing systems, including ease of 
manufacturing and of release modulation, as well as reproducibility of release profiles. 
Formulation and Process Variables 
           Hiremath and Saha (2008) have formulated hydrophilic controlled release matrix tablets of 
rifampicin, a poorly soluble drug, using hydroxypropyl methylcellulose (HPMC) polymer (low, 
medium, and high viscosity) by direct compression method. Influence of formulation variables and 
process parameters such as drug:HPMC ratio, viscosity grade of HPMC, drug particle size, and 
compression force on the formulation characters and drug release has been studied. Their results 
indicated that the release rate of the drug and the mechanism of release from the HPMC matrices are 
mainly controlled by the drug:HPMC ratio and viscosity grade of the HPMC. In general, decrease in 
the drug particle size decreased the drug release. Lower viscosity HPMC polymer was found to be 
more sensitive to the effect of compression force than the higher viscosity. 
           Ravi et al., (2008) have designed oral controlled release (CR) matrix tablets of zidovudine 
(AZT) using HPMC, EC and carbopol-971P (CP) and studied the effect of various formulation factors 
on in vitro drug release. . Release rate decreased with increase in polymer proportion and compression 
force. The release rate was lesser in formulations prepared using CP (20%) as compared to HPMC 
(20%) as compared to EC (20%). No significant difference was observed in the effect of pH of 
dissolution media on drug release from formulations prepared using HPMC or EC, but significant 
difference was observed in CP based formulations. Decrease in agitation speed from 100 to 50 rpm 
decreased release rate from HPMC and CP formulations but no significant difference was observed in 
EC formulations. Mechanism of release was found to be dependent predominantly on diffusion of 
drug through the matrix than polymer relaxation incase of HPMC and EC formulations, while 
polymer relaxation had a dominating influence on drug release than diffusion incase of CP 
formulations. Designed CR tablets have shown an initial release of 17-25% in first hour and extending 
the release up to 16-20 hours. 
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            Roberts et al., (2007) have studied the release profiles of aspirin from hypromellose matrices 
in hydro-ethanolic media. Percent aspirin released increased with increasing levels of ethanol in the 
dissolution media, correlating with the drug's solubility, however, dose dumping of aspirin did not 
occur. An initial rapid release was observed in media comprising 40% ethanol. Release in these 
conditions was considered to be both erosion and diffusion-mediated, in contrast to the release in 0, 
10, 20 and 30% ethanol media, where erosion-controlled release dominated. Image analysis of matrix 
swelling indicated a slower initial interaction between ethanol and hypromellose accounting for the 
initial rapid release. Cloud point studies suggested that ethanol retarded hydration of the polymer.  
             Sinju et al., (2004) have described the effects of temperature and humidity on tablets 
containing kollidon® SR using diphenhydramine HCl as a model drug. Exposure of tablets to 
accelerated stability condition (40°C/75%RH) in an open dish resulted in rapid increases in tablet 
hardness, accompanied by step-wise decreases in dissolution rate.  But exposure to 25°C/60%RH 
similarly resulted in increases in tablet hardness, although with minimal impact on dissolution. 
Exposure of kollidon® SR tablets to the aqueous coating process indeed resulted in noticeable changes 
in both hardness and dissolution. Application of the opadry solution appears to affect tablet behavior 
to a lesser degree, compared to water, most likely due to protection via formed barrier film. Therefore 
the authors concluded that attention needs to be paid to the extreme sensitivity of kollidon® SR matrix 
tablets to temperature and moisture during product development.  
Silvina et al., (2002) have developed HPMC matrix tablets of diclofenac sodium, evaluated 
the relationship and influence of different content levels of microcrystalline cellulose (MCC), starch, 
and lactose, in order to achieve a zero-order release. They found that each of these compounds was 
capable of interacting to some extent with each other to control drug release. 
            Paul et al., (1995) have investigated the effects of lubricant magnesium stearate at different 
concentrations, mixing shear rate, and mixing times on the tablet properties and  
drug dissolution from controlled release matrix tablets containing HPMC K4M. Diphenhydramine 
HCl and hydrochlorothiazide were chosen as the model drugs. Spray –dried hydrous lactose (Fast-Flo 
Lactose) and anhydrous dibasic calcium phosphate (A-TAB) were chosen as the model fillers.  
Tablets containing A-TAB, which compacts via a brittle fracture mechanism, were harder and had 
significantly better friability patterns than those prepared using Fast Flo Lactose. The compaction of 
Fast Flo Lactose appears to be a combination of brittle fracture and plastic deformation. Mixes 
containing lower levels of lubricant (0.2%) generated tablets that had higher crushing strengths than 
those with higher lubricant levels (2.0%). Drug release was impacted to the greatest extent by the 
solubility of the drug and excipients/filler but was only slightly affected by the level of magnesium 
stearate and duration of mixing.   
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AIM AND OBJECTIVE 
Aim  
 The present work is aimed at preparing and evaluating sustained-release (SR) matrix  tablets 
of timolol maleate (TM) using different polymers.  
 To study the effect of nature (hydrophilic and hydrophobic) of the polymer and drug: polymer 
ratio (1:0.5, 1:1and 1:1.5) on the rate of drug release. 
Objective 
           Timolol maleate is a non-selective beta-adrenergic receptor blocker used in the treatment of 
essential hypertension, glaucoma, migraine, and for prophylaxis after myocardial infraction. It is 
rapidly and nearly completely (about 90%) absorbed from the gastrointestinal tract (GIT) following 
oral ingestion, showing 60% bioavailability. Detectable plasma levels occur within one-half hour and 
peak plasma levels occur in about 1-2 hours. A plasma half-life is 4 hours. In the treatment of 
hypertension the usual initial dosage is 10 mg twice a day, whether used alone or added to diuretic 
therapy. Dosage may be increased or decreased depending on heart rate and blood pressure response. 
The usual total maintenance dosage is 20-40 mg per day. Increases in dosage to a maximum of 60 mg 
per day divided into two doses may be necessary (Thomson, 2006). 
             Although conventional tablets of Timolol maleate available in the market commercially, no 
study has been done so far for preparing the Timolol maleate sustained-release tablets. To improve the 
oral bioavailability and to reduce the dose dependent toxicity there is a need for the development of 
sustained-release formulations. Many patent technologies also indicated that Timolol maleate is 
suitable for the sustained-release (Gregory et al., 2004; Mandana et al., 2000). 
In-vivo drug release, biopharmaceutical evaluation, and in-vitro/in-vivo correlations were 
beyond the scope of this study and will be considered in future work. 
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PLAN OF WORK 
¾ Selection of Drug and Excipients profile. 
¾ List of equipments and manufacturers. 
¾ Construction of the calibration curve for timolol maleate in 0.1N HCl and 6.8 pH phosphate 
buffer. 
¾ Calculation of the dose and to construct theoretical release profile of timolol maleate from 
sustained –release formulations. 
¾ Preparation of SR formulations of TM using MCC as a diluent, following polymers at 
different concentrations and combinations by wet granulation technique. 
• HPMC K15M 
• HPMC K100M CR 
• Ethylcellulose 
¾ Evaluation tests for the Precompression blend and prepared tablets. 
¾ Selection of the best batch of tablets based on the in-vitro release studies and similarity factor 
analysis. 
¾ Release kinetics studies. 
¾ To perform swelling and erosion studies, FTIR studies, and stability studies for the optimized 
formulation. 
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Drug Profile  
TIMOLOL MALEATE 
                 Timolol maleate is a nonselective beta-adrenergic receptor blocking agent. It possesses an 
asymmetric carbon atom in its structure and is provided as the levo isomer. 
Description 
Nomenclature 
• Generic Name: Timolol Maleate 
• Chemical Name: (S)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-     
thiadiazol-3-yl]oxy]-2-propanol (Z)-2-butenedioate (1:1) salt. 
• Trade Names: Blocadren, Betim, Timoster, Betimol, Novo-Timol, Timoptic. 
 Formula 
• Empirical Formula: C13H24N4O3S•C4H4O4 
• Structural Formula 
     
 
 
Physical and Chemical Properties 
• Molecular weight     - 432.50. 
• Color     - White  
• Nature                       -       Crystalline powder 
• Odour                        - Odourless 
• Melting point - 201.5-202.5 °C 
• Solubility       -   Freely soluble in water; soluble in ethanol and methanol. Sparingly soluble in 
chloroform, practically insoluble in ether and cyclohexane. 
• pKa                          -         3.9 
Pharmacokinetics 
            Timolol maleate is rapidly and nearly completely absorbed (about 90%) following oral 
ingestion. Detectable plasma levels of Timolol occur within one-half hour and peak plasma levels 
occur in about one to two hours. The drug half-life in plasma is approximately 4 hours and this is 
essentially unchanged in patients with moderate renal insufficiency. The absolute bioavailability 
after oral administration has been reported to be approximately 60%. Timolol is not extensively 
bound to plasma proteins; i.e., < 10% by equilibrium dialysis and approximately 60% by 
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ultrafiltration. It is extensively (80%) metabolized in liver via the cytochrome P450 2D6 
isoenzyme, the metabolites being excreted in urine together with some unchanged Timolol. 
Plasma levels following oral administration are about half those following intravenous 
administration indicating approximately 50% first pass metabolism. It crosses the placenta and 
appears in breast milk. 
Pharmacology 
i)   Indications and Dosage  
• Hypertension: The usual initial dosage of Timolol maleate is 10 mg twice a day, whether 
used alone or added to diuretic therapy. Dosage may be increased or decreased depending on 
heart rate and blood pressure response. The usual total maintenance dosage is 20 to 40 mg per 
day. Increases in dosage to a maximum of 60 mg per day divided into two doses may be 
necessary. There should be an interval of at least 7 days between increases in dosages.  
      Timolol maleate tablets may be used with a thiazide diuretic or with other antihypertensive 
agents. Patients should be observed carefully during initiation of such concomitant therapy. 
• Myocardial Infarction: The recommended dosage for long-term prophylactic use in patients 
who have survived the acute phase of a myocardial infarction is 10 mg given twice daily. 
• Migraine: The usual initial dosage of Timolol maleate is 10 mg twice a day. During 
maintenance therapy the 20 mg daily dosage may be administered as a single dose. Total daily 
dosage may be increased to a maximum of 30 mg, given in divided doses, or decreased to 10 mg 
once per day, depending on clinical response and tolerability. If a satisfactory response is not 
obtained after 6 to 8 weeks use of the maximum daily dosage, therapy with Timolol should be 
discontinued. 
• Glaucoma: Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure 
in patients with ocular hypertension or open-angle glaucoma. 
 
ii) Contraindications 
    Timolol maleate is contraindicated in patients with bronchial asthma or with a history of 
bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second- and 
third-degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to this 
product. 
iii) Mechanism of Action 
   Mechanism of action like propranolol and nadolol, timolol competes with adrenergic 
neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and 
vascular smooth muscle and beta(2)-receptors in the bronchial and vascular smooth muscle. Beta(1)-
receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease 
in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic 
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hypotension. Beta (2)-blockade results in an increase in peripheral vascular resistance. The exact 
mechanism whereby Timolol reduces ocular pressure is still not known. The most likely action is by 
decreasing the secretion of aqueous humor. 
iv) Drug Interactions 
       Timolol has some interactions with the drugs like catecholamine-depleting drugs such as 
reserpine, non-steroidal anti-inflammatory drugs, calcium antagonists, digitalis, quinidine and 
clonidine. 
v) Adverse Effects 
        Fatigue, bradycardia, nausea, dizziness, bronchial spasm, pruritis. But it is usually well 
tolerated in properly selected patients. Most adverse effects have been mild & transient. 
vi) Precautions 
        Timolol maleate has been detected in human milk. Because of the potential for serious 
adverse reactions from Timolol in nursing infants, a decision should be made whether to discontinue 
nursing or to discontinue the drug, taking into account the importance of the drug to the mother. 
Safety and effectiveness in pediatric patients have not been established. 
vii)Toxicity 
        LD50=1190 mg/kg (oral, mice) 
        LD50=900 mg/kg (oral, rat). 
Pharmacodynamics 
         Timolol maleate is a beta1 and beta2 (nonselective) adrenergic receptor blocking agent that 
does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic 
activity. Clinical pharmacology studies have confirmed the beta-adrenergic blocking activity as 
shown by (1) changes in resting heart rate and response of heart rate to changes in posture; (2) 
inhibition of isoproterenol-induced tachycardia; (3) alteration of the response to the valsalva 
maneuver and amyl nitrite administration; and (4) reduction of heart rate and blood pressure changes 
on exercise. Timolol decreases the positive chronotropic, positive inotropic, bronchodilator, and 
vasodilator responses caused by beta-adrenergic receptor agonists. 
           Clinical studies indicate that Timolol maleate at a dosage of 20 to 60 mg/day reduces blood 
pressure without causing postural hypotension in most patients with essential hypertension. 
Administration of Timolol to patients with hypertension results initially in a decrease in cardiac 
output, little immediate change in blood pressure, and an increase in calculated peripheral resistance. 
With continued administration of Timolol, blood pressure decreases within a few days, cardiac output 
usually remains reduced, and peripheral resistance falls toward pretreatment levels. Plasma volume 
may decrease or remain unchanged during therapy with Timolol. In the majority of patients with 
hypertension Timolol also decreases plasma renin activity. Dosage adjustment to achieve optimal 
antihypertensive effect may require a few weeks. When therapy with Timolol is discontinued, the 
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blood pressure tends to return to pretreatment levels gradually. In most patients the antihypertensive 
activity of Timolol is maintained with long-term therapy and is well tolerated. 
Method of analysis 
• Spectroscopy like-IR, NMR, Mass and UV-Visible Spectroscopy. 
• Thin Layer Chromatography 
• High Performance Liquid Chromatography 
Storage 
Tablets should be stored at 20° to 25°C (68° to 77°F), protected from light. Dispense in a well-
closed, light-resistant container. 
Official preparations  
• IP, 1996:   Timolol Maleate eye drops. 
   Timolol Maleate tablets. 
• BP, 1993: Timolol eye drops, Timolol tablets. 
• USP/NF, 2004: Timolol Maleate & Hydrochlorthiazide tablets.     
                                      Timolol Maleate opthalmic solution. 
                                Timolol Maleate tablets. 
Proprietary preparations 
•    Opthalmic solutions : Timol  (India)  
                                                            Timoptic 0.25%, 0.5% (USA) 
• Tablets :     Timostar 10mg, 20mg (Mankind Pharma, India) 
                                          Blocadren  5 mg, 10 mg, 20 mg (Merck & Co., USA) 
                                          Betim (UK) 
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 Excipients profile 
The following are the different polymers and excipients used in this work (Raymond et al., 2003) 
Hypromellose 
Hypromellose is a partly O-methylated and O-(2- hydroxypropylated) cellulose. 
 
Synonyms                           : Benecel MHPC; Hydroxypropylmethylcellulose (HPMC); Methocel; 
Metolose; Tylopur. 
 
Description         : Odorless and tasteless, white or creamy-white fibrous or                           
granular powder. 
 
Grades                          :   Methocel K100 Premium LVEP, Methocel K4M, K15M, K100M,   
Metolose 60SH, 65SH, 90SH. 
 
Stability                                    :           Stable material, although it is hygroscopic after drying. 
 
Acidity/alkalinity                     :          pH = 5.5–8.0 for a 1% w/w aqueous solution 
 
Density (true)                          :          1.326 g/cm3. 
 
Melting point                          :         Browns at 190–200°C; chars at 225–230°C. Glass transition        
temperature is 170–180°C. 
 
Viscosity                                 :         Ranges from 3-100000 mPa s. 
                                    Methocel K100M (100000 mPa s),  
                                    Methocel  K15M (15000 mPa s), 
                                    Methocel K4M (4000 mPa s). 
 
Safety                                   :       Non-toxic and non-irritant material, although excessive 
                                                     oral consumption may have a laxative effect. 
 
Uses                                     :       As a tablet binder (2% - 5% w/w), 
                                                    Matrix former (10% - 80% w/w), 
                                                   Thickening agent (0.45% - 1% w/w), 
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                                          It is also used as an emulsifier, suspending agent, and stabilizing agent in 
topical gels and ointments. 
 
Ethylcellulose 
Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer of β-anhydroglucose units joined 
together by acetal linkages. 
 
Synonyms                            :        Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
 
Description                         :        It is a tasteless, free-flowing, white to light tan-colored   powder. 
 
      Functional Category          :       Coating agent; flavoring fixative; tablet binder; tablet filler;    
viscosity agent. 
 
Solubility    :   It is practically insoluble in glycerin, propylene glycol, and 
water.Ethylcellulose that contains less than 46.5% of ethoxyl 
groups is freely soluble in chloroform, methyl acetate, and 
tetrahydrofuran, and in mixtures of aromatic hydrocarbons with 
ethanol (95%).Ethylcellulose that contains not less than 46.5% of 
ethoxyl groups is freely soluble in chloroform, ethanol (95%), ethyl 
acetate, methanol, and toluene. 
 
Density (bulk)                :     0.4 g/cm3 
 
Viscosity                         :     7 to 100 mPa s 
 
 Stability and Storage :    It is a stable, slightly hygroscopic material. It should be stored at a 
temperature not exceeding 32°C (90°F) in a dry area away from all 
sources of heat. It should not be stored next to peroxides or other 
oxidizing agents. 
 
Safety                      :     It is generally regarded as a nontoxic, nonallergenic, and nonirritating 
material. It is not metabolized following oral consumption and is 
therefore a noncalorific substance. 
 
Uses                                  :      It is used in the microencapsulation (10-20% w/w). 
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                                        As a sustained-release tablet coating (3-20% w/w). 
                                        It can be used for tablet coating and tablet granulation  
                                        (1- 3% w/w). 
 
Microcrystalline cellulose 
 
Microcrystalline cellulose is purified, partially depolymerized cellulose. 
 
   Synonyms                        :      Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; 
Vivapur. 
 
Description                     :      It occurs as a white, odorless, tasteless, crystalline powder composed of 
porous particles. 
 
Grades                           :       Avicel PH-101, PH-102, PH-103; Emcocel 50M,  90M; Vivapur 101, 
102. 
 
Functional Category     :       Adsorbent; suspending agent; tablet and capsule diluent;     tablet 
disintegrant. 
 
Solubility                       :       Slightly soluble in 5% w/v sodium hydroxide solution;     practically 
insoluble in water, dilute acids, and most organic solvents. 
 
Melting point                :     Chars at 260-270°C. 
 
Stability and Storage    :     It is a stable though hygroscopic material. The bulk material should be 
stored in a well-closed container in a cool, dry place. 
 
Safety                            :      It is a relatively nontoxic and nonirritant material. 
 
Uses                               :     It is widely used as a diluent (20 – 90 %w/w). 
                                             As a tablet disintegrant (5-15% w/w). 
                                             It can be used as an adsorbent, antiadherent (20-   90%w/w). 
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Povidone 
Synonyms                         :           E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-  
pyrrolidinyl)ethylene]; polyvidone; polyvinylpyrrolidone; PVP; 1-
vinyl-2-pyrrolidinone polymer. 
 
Grades                              :            PVP K-12, K-15, K-17, K-25, K-30, K-60, K-90, K-120. 
 
Functional Category       :       Disintegrant; dissolution aid; suspending agent; tablet binder. 
 
Description                      :          It occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. 
 
Melting point                 :          Softens at 150°C. 
 
Solubility                    :   Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; practically insoluble in ether, hydrocarbons, and mineral oil. In 
water, the concentration of a solution is limited only by the viscosity of the 
resulting solution, which is a function of the K-value. 
 
Stability and Storage   :  Povidone darkens to some extent on heating at 150°C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–
130°C; steam sterilization of an aqueous solution does not alter its 
properties. Aqueous solutions are susceptible to mold growth and 
consequently require the addition of suitable preservatives.  
                                           It may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, 
it should be stored in an airtight container in a cool, dry place. 
 
 Incompatibilities      :    It is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, 
tannin, and other compounds; the efficacy of some preservatives, e.g. 
thimerosal, may be adversely affected by the formation of complexes with 
povidone. 
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Safety                             : When consumed orally, povidone may be regarded as essentially nontoxic 
since it is not absorbed from the gastrointestinal tract or mucous 
membranes. It additionally has no irritant effect on the skin and causes no 
sensitization. 
 
Uses                    : In tableting, povidone solutions (0.5-5% w/v) are used as binders in wet-
granulation processes. It is also added to powder blends in the dry form and 
granulated in situ by the addition of water, alcohol, or hydroalcoholic 
solutions. It is used as a solubilizer in oral and parenteral formulations and 
has been shown to enhance dissolution of poorly soluble drugs from solid-
dosage forms. Povidone solutions may also be used as coating agents. It is 
additionally used as a suspending, stabilizing, or viscosity-increasing agent 
in a number of topical and oral suspensions and solutions. The solubility of 
a number of poorly soluble active drugs may be increased by mixing with 
povidone. 
Talc  
Talc is a purified, hydrated, magnesium silicate. 
 
Synonyms     :     Altalc; E553b; Hydrous magnesium calcium silicate; Hydrous magnesium silicate; 
Luzenac Pharma; Magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil 
Star; Powdered talc; Purified French chalk; Purtalc; Soapstone; Steatite; Superiore. 
 
Description  :     Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free 
from grittiness. 
 
Functional Category  :  Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
 
Solubility                  :     Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
 
Stability and Storage   : Talc is a stable material and may be sterilized by heating at 160°C for not 
less than 1 hour. It may also be sterilized by exposure to ethylene oxide or 
gamma irradiation. It should be stored in a well-closed container in a cool, 
dry place. 
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Safety                 :  Talc is used mainly in tablet and capsule formulations. It is not absorbed 
systemically following oral ingestion and is therefore regarded as an 
essentially nontoxic material. However, intranasal or intravenous abuse of 
products containing talc can cause granulomas in body tissues, particularly 
the lungs. Contamination of wounds or body cavities with talc may also 
cause granulomas; therefore, it should not be used to dust surgical gloves. 
Inhalation of talc causes irritation and may cause severe respiratory distress 
in infants. 
Incompatibilities      :     Incompatible with quaternary ammonium compounds. 
 
Uses                       :     Talc can be used in oral solid dosage formulations as a lubricant and diluent. 
However, it is widely used as a dissolution retardant in the development of 
controlled-release products. It is also used as a lubricant in tablet 
formulations; in a novel powder coating for extended-release pellets; and as 
an adsorbent. In topical preparations, talc is used as a dusting powder, 
although it should not be used to dust surgical gloves. 
                                        Talc is additionally used to clarify liquids and is also used in cosmetics and 
food products, mainly for its lubricant properties. 
 
Magnesium Stearate 
 
Synonyms                     :      Magnesium octadecanoate; Octadecanoic acid, magnesium  salt; Stearic 
acid, magnesium salt. 
 
Functional Category   :    Tablet and capsule lubricant. 
 
Description                :   It is a very fine, light white, precipitated or milled, impalpable powder of low    
bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
 
Flowability                :      Poorly flowing, cohesive powder. 
 
Melting range           :      117–150°C (commercial samples); 
                                           126–130°C (high purity magnesium stearate). 
 
Solubility                   :      Practically insoluble in ethanol, ethanol (95%), ether and       water; slightly 
soluble in warm benzene and warm ethanol (95%). 
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Stability and Storage  :    It  is stable and should be stored in a well-closed container in a cool, dry 
place. 
 
Incompatibilities     :  Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. It cannot be used in products containing aspirin, 
some vitamins, and most alkaloidal salts. 
 
Safety                          :    Nontoxic following oral administration. However, oral consumption of 
large quantities may produce a laxative effect or mucosal irritation. 
 
Uses                        :     It is widely used in cosmetics, foods, and pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier 
creams. 
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METHODOLOGY 
LIST OF MATERIALS 
Table 5. List of Materials 
 
LIST OF INSTRUMENTS  
Table 6. List of Instruments 
S. No. Instruments Manufacturer 
1. Electronic Weighing Balance Shimadzu, AUX 220, Japan. 
2. 16 Station Rotary Tableting 
Machine  
Cadmach Machinery Co, Ahmedabad, India. 
3. Tap Density Tester (U.S.P.) Electrolab, ETD-1020, India. 
4. Hardness Tester (Monsanto) Cadmach Machinery Co, Ahmedabad, India. 
5. Digital Vernier Caliper Mitutoyo Corp, Kawasaki, Japan 
6. Sieves Rolex standard sieves. Hyderabad, India. 
S. No. Material Supplied by 
1. Timolol Maleate 
(BP/USP) 
Gift sample from Granules India Pvt. Ltd, Hyd. 
2. HPMC K15M Gift sample from  Granules India Pvt. Ltd, Hyd. 
3. HPMC K100M CR Gift sample from  Granules India Pvt. Ltd, Hyd. 
4. Ethylcellulose-N-20 Gift sample  Granules India Pvt. Ltd, Hyd. 
5. Microcrystalline cellulose 
(Avicel PH-101) 
Granules India Pvt. Ltd, Hyd. 
6. Polyvinylpyrrolidone 
(PVP-K-90) 
Gift sample from  Granules India Pvt. Ltd, Hyd. 
7. Talc Granules India Pvt. Ltd, Hyd. 
8. Magnesium Stearate Granules India Pvt. Ltd, Hyd. 
9. Pottasium Dihydrogen 
Orthophosphate Purified 
LR 
S.D. Fine chemical Pvt. Ltd, Mumbai 
10. Sodium Hydroxide 
Pellets 
Finar Chemicals Limited, Ahmedabad. 
Reagents 
11. Hydrochloric acid Merck specialties Pvt. Ltd, Mumbai 
12. Isopropyl alcohol RFCL Ltd, New Delhi. 
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7. Dissolution Apparatus (U.S.P.) Electrolab, TDT- 08L, India. 
8. UV/Visible Spectrophotometer Systronics PC Based, 2202, Ahmedabad, 
India. 
9. Hot- Air Oven Biotechnics Pvt. Ltd, India. 
10. Friability Test Apparatus Campbell Electronics, Mumbai, India. 
11. pH Meter L I 120, Elico Pvt. Ltd, India. 
 
 
Construction of Standard Graph of Timolol Maleate 
 Accurately weighed amount of 100 mg Timolol maleate was transferred into a 100ml 
volumetric flask. 20 mL of 0.1N hydrochloric acid (HCl) was added to dissolve the drug and volume 
was made up to 100 mL with the same HCl. The resulted solution had the concentration of 1mg/ml 
which was labeled as ‘stock’. From this stock solution 10ml was taken and diluted to 100 mL with 
0.1N HCl which has given the solution having the concentration of 100mcg/mL. Necessary dilutions 
were made by using this second solution to give the different concentrations of Timolol maleate ( 5 to 
50 mcg/mL) solutions.                       
             The absorbances of above solutions were recorded at λmax (295 nm) of the drug using double 
beam UV-Visible spectrophotometer. Standard graph was plotted between the concentration (on X-
axis) and absorbance (on Y-axis). 
             Similarly, standard graph was plotted with 6.8 pH phosphate buffer. 
 
Preparation of 0.1 N HCl: Accurately measured 8.5 mL of concentrated hydrochloric acid was 
added to 1000 mL of distilled water. 
Preparation of pH 6.8 phosphate buffer:  Accurately measured 50 mL of 0.2 M potassium 
dihydrogen orthophosphate was transferred to a 200mL volumetric flask and 22.4 mL of 0.2 M 
sodium hydroxide was added to it. Volume was made up to 200 mL with distilled water, mixed and 
pH was adjusted to 6.8 with 0.2 M sodium hydroxide or 0.2 M orthophosphoric acid.  
Preparation of 0.2 M potassium dihydrogen phosphate solution: Accurately weighed 27.218 g of 
monobasic potassium dihydrogen phosphate was dissolved in 1000 mL of distilled water and mixed. 
Preparation of 0.2 M sodium hydroxide solution: Accurately weighed 8 g of sodium hydroxide 
pellets were dissolved in 1000 mL of distilled water and mixed. 
Calculation of Sustained-Release Dose and Theoretical Release Profile of Timolol Maleate 
             The total dose of Timolol maleate for twice-daily SR formulation was calculated by Robinson 
Eriksen (Robinson and Eriksen, 1966) equation using available pharmacokinetic data. 
 The zero-order drug release rate constant (k0) was calculated using following equation 
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                                               k0 = DI x ke   
 where DI is the initial dose (i.e., conventional dose = 10 mg) and ke is first-order rate constant for 
overall elimination. 
                                                ke   =   0.693 / t1/2     
where t1/2 = Biological half-life of timolol maleate = 4 h     
                         Therefore         ke = 0.693 / 4                
                                                      = 0.1732 mg/h. 
                       Availability rate  R =  ke x DI 
                                                       = 0.1732 x 10 
                                                       = 1.732 mg/h. 
                        Loading dose = DL = DI – R x tmax 
                             where tmax  = 2 h 
                         Therefore DL = 10-(1.732 x 2) 
                                                = 6.54 mg. 
     
           Maintenance dose = DM = R x H 
 where H = Number of hours for which sustained action is desired after initial release.   
                    
                Therefore DM = 1.732 x 11 
                                        = 19.05 mg. 
 
                       Total dose required = DT = DL + DM 
                                         = 6.54+19.05 
                                         = 25.59 mg 
                                         ≅25 mg 
         
            Hence an oral controlled release formulation of timolol maleate should contain a total dose of   
25 mg and should release 6.54 mg in first 1 hour like conventional tablets, and 1.73 mg/h up to 12 
hours thereafter.       
Preparation of Timolol Maleate Matrix Tablets 
            All the matrix tablets, each containing 25 mg of Timolol maleate, were prepared by wet 
granulation method. 
Wet granulation: Drug and the diluent (MCC or Lactose) were sifted through sieve No. 40 manually 
and mixed well to ensure the uniformity of premix blend. Several drug-diluent premixes were then 
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mixed with the selected ratio of polymer(s), previously sifted through sieve No. 40, for 5 minutes. 
Premix blend was wet granulated with 5% w/v solution of PVP K-90 in a mortar. The wet mass was 
passed through No.18 sieve. The wet granules were dried at 55°C ± 5°C for 1 hour in a hot-air oven 
and the dried granules were sieved through No.22 sieve. 
               These granules were blended with lubrication mixture (1% w/w magnesium stearate and 2% 
w/w talc) and compressed using 16 station rotary tableting machine, equipped with flat-faced, round 
punches of 6-mm diameter. 
           The drug polymer ratio was developed to adjust drug release as per theoretical release profile 
and to keep total weight of tablet constant for all the fabricated batches under experimental conditions 
of preparations. The total weight of the matrix tablets was 120mg with different drug polymer ratios 
like 1:0.5, 1:1, 1:1.5. The various polymers used were HPMC K15M, HPMC K100M CR and Ethyl 
cellulose. MCC is used as diluent for the preparation of matrix tablets. 
Table 7 . List of Different Formulations                    
Formulae Polymer (s)  Diluent         Method 
F1 to F3 HPMC K15M MCC Wet granulation 
F4 to F6 HPMC K 100M MCC Wet granulation 
F7 to F9 Ethyl cellulose MCC Wet granulation 
F10 to F12 HPMC K100M & EC MCC Wet granulation 
 
Formulations 
         In the formulations prepared, the release retardants included were hydroxypropylmethylcellulose 
(HPMC K15M, HPMC K100M CR),  Ethylcellulose (EC). Microcrystalline cellulose (MCC) was 
used as diluent. Magnesium stearate (MS) 1% and talc 2 % were used as lubricants. 5% w/v solution 
of polyvinylpyrrolidone (PVP-K90) in isopropyl alcohol (IPA) was used as binder. Compositions of 
different formulations were given in the following Tables (Table 8 to Table 11). 
     Table 8 . Composition of Matrix Tablets Containing HPMC K15M 
F.Code  TM 
(mg) 
HPMC     
K15M 
  (mg) 
 MCC  
 (mg) 
 PVP-     
K90 
(mg) 
 IPA 
(mL) 
  MS 
 (mg) 
Talc 
(mg) 
Total 
(mg) 
F1 25 12.5 72.9 6 qs 1.2 2.4 120 
F2 25 25 60.4 6 qs 1.2 2.4 120 
F3 25 37.5 47.9 6 qs 1.2 2.4 120 
      * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1 and 1:1.5 for F1, F2 and F3 
respectively. 
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Table 9 . Composition of Matrix Tablets Containing HPMC K100M CR 
F.Code TM 
(mg) 
HPMC K 
100M 
(mg) 
MCC 
(mg) 
PVP-    
K90 
(mg) 
IPA 
(ml) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F4 25 12.5 72.9 6 qs 1.2 2.4 120 
F5 25 25 60.4 6 qs 1.2 2.4 120 
F6 25 37.5 47.9 6 qs 1.2 2.4 120 
      * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1 and 1:1.5 for  F4, F5 and F6 
respectively. 
Table 10 . Composition of Matrix Tablets Containing Ethylcellulose 
F.Code TM 
(mg) 
EC  (mg) MCC 
(mg) 
PVP-    
K90 
(mg) 
IPA 
(mL) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F7 25 12.5 72.9 6 qs 1.2 2.4 120 
F8 25 25 60.4 6 qs 1.2 2.4 120 
F9 25 37.5 47.9 6 qs 1.2 2.4 120 
     * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1 and 1:1.5 for F7, F8 and F9 
respectively. 
Table 11. Composition of Matrix Tablets Containing Combination of HPMC K100M and EC 
F.Code TM 
(mg) 
HPMC   
K100M 
(mg) 
EC 
(mg) 
MCC 
(mg) 
PVP-   
K90 
(mg) 
IPA 
(mL) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F10 25 30 20 35.4 6 Qs 1.2 2.4 120 
F11 25 25 25 35.4 6 Qs 1.2 2.4 120 
F12 25 20 30 35.4 6 Qs 1.2 2.4 120 
      * qs = quantity sufficient; Drug to Polymer ratio is 1:2; HPMC to EC ratio is 3:2, 1:1 and 2:3 for 
F10, F11and F12 respectively. 
 
 
Evaluation of Precompression Blend 
a)   Angle of Repose          
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             The angle of repose of granules was determined by the funnel-method. The accurately 
weighed granules were taken in a funnel. The height of the funnel was adjusted in such a manner that 
the tip of the funnel just touched the apex of the heap of the granules. The granules were allowed to 
flow through the funnel freely onto the surface. The diameter of the powder cone measured and angle 
of repose was calculated using the following equation (Raghuram et al., 2003). 
                                                  tan θ  = h/r 
 
where h and r are the height and radius of the powder cone, θ is the angle of repose. 
Angle of repose values less than 25, 25-30, 30-40, and more than 40 indicates excellent, good, 
passable, and poor flow properties respectively.   
 b) Determination of Bulk Density and Tapped Density 
             An accurately weighed quantity of the granules/ powder (W) was carefully poured into the 
graduated cylinder and volume (V0) was measured. Then the graduated cylinder was closed with lid 
and set into the tap density tester (USP). The density apparatus was set for 100 tabs and after that the 
volume (Vf) was measured and continued operation till the two consecutive readings were equal 
(Lachman et al., 1987). 
            The bulk density and the tapped density were calculated using the following formulae. 
 
                                   Bulk density = W/V0 
                                  Tapped density = W/Vf 
 
                         where, W= Weight of the powder 
                                     V0 = Initial volume 
                                      Vf = final volume 
c) Compressibility Index (Carr’s Index) 
               Carr’s index (CI) is an important measure that can be obtained from the bulk and tapped 
densities. In theory, the less compressible a material the more flowable it is (Lachman et al., 1987). 
                                    CI = (TD-BD) x 100/TD    
                where, TD is the tapped density and BD is the bulk density. 
                       Table 12 .Carr’s Index Values 
 S.No. Carr’s Index Properties 
1 5-12 Free flowing 
2 13-16 Good 
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3 18-21 Fair 
4 23-35 Poor 
5 33-38 Very poor 
6 >40 Extremely poor 
 
d)  Hausner’s Ratio               
             It is the ratio of tapped density and bulk density. Hausner found that this ratio was related to 
interparticle friction and, as such, could be used to predict powder flow properties (Lachman et al., 
1987). Generally a value less than 1.25 indicates good flow properties, which is equivalent to 20% of 
Carr’s index.  
Evaluation of Matrix Tablets 
i) Thickness 
               Twenty tablets from the representative sample were randomly taken and individual tablet 
thickness was measured by using digital vernier caliper. Average thickness and standard deviation 
values were calculated. 
ii) Hardness 
                Tablet hardness was measured by using Monsanto hardness tester. From each batch six 
tablets were measured for the hardness and average of six values was noted along with standard 
deviations. 
iii) Friability Test 
          From each batch, ten tablets were accurately weighed and placed in the friability test apparatus 
(Roche friabilator). Apparatus was operated at 25 rpm for 4 minutes and tablets were observed while 
rotating. The tablets were then taken after 100 rotations, dedusted and reweighed. The friability was 
calculated as the percentage weight loss. 
Note: No tablet should stick to the walls of the apparatus. If so, brush the walls with talcum powder. 
There should be no capping also. 
  % friability was calculated as follows 
               
                                 % Friability = (W1 – W2) x 100/W1 
 
                             where W1 = Initial weight of the 20 tablets. 
                                       W2 = Final weight of the 20 tablets after testing. 
 
Friability values below 0.8% are generally acceptable. 
iv) Weight Variation Test  
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           To study weight variation individual weights (WI) of 20 tablets from each formulation were 
noted using electronic balance. Their average weight (WA) was calculated. Percent weight variation 
was calculated as follows. Average weights of the tablets along with standard deviation values were 
calculated. 
                            % weight variation = (WA–WI) x 100/ WA 
           As the total tablet weight was 120 mg, according to IP 1996, out of twenty tablets ±7.5 % 
variation can be allowed for not more than two tablets. 
           According to USP 2004, ±10% weight variation can be allowed for not more than two tablets 
out of twenty tablets. 
v) Drug Content (Assay) 
           The drug content of the matrix tablets was determined according to in-house standards and it 
meets the requirements if the amount of the active ingredient in each of the 10 tested tablets lies 
within the range of 90% to 110% of the standard amount. 
            Ten tablets were weighed and taken into a mortar and crushed into fine powder. An accurately 
weighed portion of the powder equivalent to about 100 mg of TM was transferred to a 100 mL 
volumetric flask containing 70 mL of 0.1N HCl. It was shaken by mechanical means for 1h.Then it 
was filtered through a Whatman filter paper (No. 1) and diluted to 100 mL with 0.1N HCl. From this 
resulted solution 1 mL was taken, diluted to 50 mL with 0.1N HCl and absorbance was measured 
against blank at 295 nm. 
       
vi) In -Vitro Drug Release Characteristics 
           Drug release was assessed by dissolution test under the following conditions: n = 3,  USP type 
II dissolution apparatus  (paddle method) at 100 rpm in 500 mL of  0.1N HCl for first 2 hours and the 
phosphate buffer pH 6.8 from 3 to 12 hours, maintained at 37°C ± 0.5°C.  An aliquot (5mL) was 
withdrawn at specific time intervals and replaced with the same volume of prewarmed (37°C ± 0.5°C) 
fresh dissolution medium. The samples withdrawn were filtered through Whatman filter paper (No.1) 
and drug content in each sample was analyzed by UV-visible spectrophotometer at 295 nm.     
vii) Kinetic Analysis of Dissolution Data 
             To analyze the in vitro release data various kinetic models were used to describe the release 
kinetics. The zero order rate Eq. (1) describes the systems where the drug release rate is independent 
of its concentration (Hadjiioannou et al., 1993). The first order Eq. (2) describes the release from 
system where release rate is concentration dependent (Bourne, 2002). Higuchi (1963) described the 
release of drugs from insoluble matrix as a square root of time dependent process based on Fickian 
diffusion Eq. (3). The Hixson-Crowell cube root law Eq. (4) describes the release from systems where 
there is a change in surface area and diameter of particles or tablets (Hixson and Crowell, 1931). 
 
                  C = K0 t                                                                                                  (1)                  
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where, K0 is zero-order rate constant expressed in units of concentration/time and t is the time. 
                  LogC = LogC0  - K1 t / 2.303                                                                  (2) 
 
where, C0 is the initial concentration of drug and K1 is first order constant. 
  
                 Q = KHt1/2                                                                                                         (3) 
where, KH is the constant reflecting the design variables of the system. 
          
 
                  Q01/3 – Qt1/3 = KHC t                                                                                   (4) 
where, Qt is the amount of drug remained in time t, Q0 is the initial amount of the drug in tablet and 
KHC is the rate constant for Hixson-Crowell rate equation. 
 
 The following plots were made using the in-vitro drug release data 
 
Cumulative % drug release vs. time (Zero order kinetic model); 
 Log cumulative of % drug remaining vs. time (First order kinetic model); 
Cumulative % drug release vs. square root of time (Higuchi model); 
And cube root of initial concentration minus the cube root of percentage of drug remaining in the 
matrix vs. time (Hixson-Crowell cube root law). 
                                               
viii) Mechanism of drug release 
 
             Korsmeyer et al (1983) derived a simple relationship which described drug release from a 
polymeric system Eq. (5). To find out the mechanism of drug release, first 60% drug release data was 
fitted in Korsmeyer–Peppas model. 
 
                                      Mt / M∞ = Ktn                                                                    (5)              
 
where Mt / M∞ is fraction of drug released at time t, K is the release  rate constant incorporating 
structural and geometric characteristics of the tablet, and n is the release exponent. The n value is used 
to characterize different release mechanisms.  
 
            A plot of log cumulative % drug release vs. log time was made. Slope of the line was n. The n 
value is used to characterize different release mechanisms as given in Table16, for the cylindrical 
shaped matrices. Case-II generally refers to the erosion of the polymeric chain and anomalous 
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transport (Non-Fickian) refers to a combination of both diffusion and erosion controlled-drug release 
(Peppas, 1985). 
Table 13 .   Diffusion Exponent and Solute Release Mechanism for Cylindrical Shape  
 
 
 
 
 
 
 
 
ix) Similarity Factor (f2) Analysis 
               In vitro release profiles of the selected batches (F6 and F11) of sustained release tablets were 
compared with the theoretical release profile which was calculated earlier. The data were analyzed by 
the following formula ((Bolton and Bon., 2004). 
 
                                f2 = 50 log {[1+ (1/N) ∑ (Ri – Ti)2 ]-0.5 x 100}                                          
 where N = number of time points, Ri and Ti = dissolution of reference and test products at time i. If f2 
is greater than 50 it is considered that 2 products share similar drug release behaviors. 
 
x) Swelling and Erosion Studies 
             Swelling and eroding behavior was determined by a method similar to that reported by 
Avachat and Vikram (Avachat and Vikram, 2007).The dissolution jars were marked with the time 
points of   0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours. One tablet was placed in each dissolution jar 
containing 500 mL of 0.1 N HCl at 37 °C ± 0.5 °C, and the apparatus was run at 100 rpm using 
paddle. After 2 hours, 0.1 N HCl was replaced with 500 mL of phosphate buffer pH 6.8. The tablets 
were taken out after completion of the respected stipulated time span as mentioned above and 
weighed after the excess of water at the surface had been removed with filter paper. The wetted 
samples were then dried in an oven at 40 °C up to constant weight. The increase of the weight on the 
tablet reflects the weight of the liquid uptake. It was estimated according to following equation  
 
                                           Q = 100(Ww – Wi) / Wi              
                                                                      
where Q is the percentage swelling, and Ww and Wi are the masses of the hydrated samples before 
drying and the initial starting dry weight, respectively (Lopes et al., 2006). 
The degree of erosion (expressed as percentage erosion of the polymer content, E) was determined 
using following equation. 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
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                                         E = 100(Wi – Wf) / Wi                                                                                      
 
where Wf is the final mass of the same dried and partially eroded sample.  
xi) FTIR Studies 
              FTIR studies were performed on drug and the optimized formulation using Shimadzu FTIR 
(Shimadzu Corp., India). The samples were analyzed between wavenumbers 4000 and 400 cm-1. 
 
xii) Stability Studies 
            
         The optimized matrix tablets were subjected to stability studies at 25°C ± 2°C / 60% ± 5% RH 
and 40°C ± 2°C / 75% ± 5%  RH The products were evaluated for their physical characteristics, drug 
content, and in-vitro drug release profiles over a period of 3 months 
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RESULTS AND DISCUSSION 
 
Standard Graph of Timolol Maleate 
            The standard graph of Timolol maleate ((Table.14 ) has shown good linearity with R2 values 
0.9956 and 0.9968 in 0.1 N HCl (Fig. 3) and pH 6.8 buffer (Fig. 4) respectively, which suggests that it 
obeys the “Beer-Lambert’s  law”. 
 
                           Table14:  Standard Graph of Timolol Maleate 
Conc. 
(mcg/mL) 
Absorbance 
0.1N HCl 6.8 pH Buffer 
5 0.159 0.135 
10 0.208 0.248 
15 0.318 0.352   
20 0.428 0.433 
25 0.512 0.535 
30 0.605 0.671 
35 0.718 0.759 
40 0.860 0.858 
45 0.932 0.934 
50 1.009 1.011 
R2 0.9956 0.9968 
 
Figure 3. Standard graph of Timolol maleate in 0.1 N HCl 
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                          Figure  4. Standard graph of Timolol maleate in 6.8 pH buffer 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dose Calculations and Theoretical Release Profile 
                    As calculated before, the total dose required for twice-daily SR formulation of Timolol 
maleate was found to be 25 mg and its theoretical release profile was given in Table 15.         
 
Table15  : Theoretical Release Profile of Timolol Maleate from SR tablets 
 
Time (hours) Cumulative % Release 
1 26.16 
2 33.08 
3 40 
4 46.92 
6 60.76 
8 74.6 
10 88.44 
12 > 90 
 
Characterization of Granules 
                The granules for matrix tablets were characterized with respect to angle of repose, bulk 
density, tapped density, Carr’s index, and drug content (Table 16). Angle of repose was less than 35° 
and Carr’s index values were less than 21 for the granules of all the batches indicating good to fair 
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flowability and compressibility. Hausner’s ratio was less than 1.25 for all the batches indicating good 
flow properties. The drug content was more than 90 % for all the granules of different formulations. 
 
Table16 : Physical Properties of Precompression Blend 
 
Formulations Angle of 
repose ( ° ) 
Bulk 
Density 
(g/mL) 
Tapped 
Density 
(g/mL) 
Carr’s 
Index (%) 
Hausner’s 
ratio 
F1 25.49 0.214 0.251 14.74 1.17 
F2 26.24 0.308 0.364 15.38 1.18 
F3 29.05 0.276 0.322 14.28 1.16 
F4 26.56 0.422 0.506 16.60 1.19 
F5 28.75 0.481 0.572 15.90 1.18 
F6 27.33 0.475 0.566 16.07 1.19 
F7 26.43 0.412 0.483 14.69 1.17 
F8 24.77 0.488 0.537 9.12 1.10 
F9 26.42 0.439 0.521 15.73 1.18 
F10 21.25 0.520 0.582 10.65 1.11 
F11 26.27 0.487 0.561 13.19 1.15 
F12 25.49 0.494 0.566 12.72 1.14 
 
Physical Evaluation of matrix tablets 
        The results of the uniformity of weight, hardness, thickness, friability, and drug content of the 
tablets are given in Table 20. All the tablets of different batches complied with the official 
requirements of uniformity of weight as their weights varied between 118.4 and 122.3 mg. The 
hardness of the tablets ranged from 5.08 to 6.16 kg/cm2 and the friability values were less than 0.8% 
indicating that the matrix tablets were compact and hard. The thickness of the tablets ranged from 
2.88 to 3.40 mm. All the formulations satisfied the content of the drug as they contained 90 to 103 % 
of Timolol maleate and good uniformity in drug content was observed. Thus all the physical attributes 
of the prepared blends were found be practically within control. 
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Table17 : Physical Evaluation of Matrix Tablets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* All values represent mean ± Standard Deviation (SD), n=3 
† All values represent mean ± Standard Deviation (SD), n=6 
‡ All values represent mean ± Standard Deviation (SD), n=20 
 
In-Vitro Drug Release Studies 
Drug Release from HPMC K15M Matrices  
           The results of release studies of formulations F1 to F3 are shown in Table 18 and Figure 5. The 
release of drug depends not only on the nature of matrix but also upon the drug polymer ratio. As the 
percentage of polymer increased, the kinetics of release decreased. Formulation F1 composed of drug 
polymer ratio of 1:0.5, failed to sustain release beyond 6h. This formulation underwent erosion before 
complete swelling could take place. Formulations with drug polymer ratios 1:1 (F2), 1:1.5 (F3) have 
extended the drug release for 8h. All these formulations have shown more than 30% release in the 
first 1 hour indicating burst release. This phenomenon may be attributed to surface erosion or initial 
disaggregation of the matrix tablet prior to gel layer formation around the tablet core (Ebube et al., 
1997). It is reported in the literature that more than 30% release of drug in the first hour of dissolution 
indicates the chance of dose dumping (Atul et al., 2006). 
 
F.Code Hardness 
(kg/cm2)  
Thickness 
(mm)  
Weight 
(mg)  
Friability 
(%) 
Drug content 
(%) 
F1 5.50 ±0.44 3.22±0.17 119.8±1.48 0.36 98.25±1.37 
F2 5.50±0.31 3.37±0.25 120.4±0.54 0.39 95.28±0.80 
F3 5.58±0.40 3.14±0.80 118.6±0.41 0.43 99.12±2.47 
F4 5.00±0.44 3.38±0.73 120.5±0.80 0.77 96.34±2.18 
F5 5.00±0.31 3.00±0.68 121.2±0.83 0.42 91.29±0.98 
F6 5.08±0.37 2.98±0.88 122.1±0.93 0.48 97.35±0.43 
F7 4.33±0.50 3.06±0.46 119.2±0.83 0.27 94.57±1.22 
F8 4.58±0.57 2.98±0.38 122.2±0.92 0.29 90.35±2.09 
F9 4.75±0.77 3.25±0.37 122.0±1.22 0.53 99.54±2.15 
F10 5.58±0.37 2.93±0.83 119.8±0.19 0.69 95.39±2.06 
F11 5.66±0.65 3.33±0.59 119.8±0.38 0.37 98.90±2.31 
F12 5.75±0.57 3.36±0.74 121.3±0.97 0.51 97.43±2.11 
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Table18 : In-Vitro Release Data of Timolol Maleate from HPMC K15M Matrices 
  
TIME 
(HOURS) 
F1 F2 F3 
1 41.94±0.87 39.96±0.93 37.12±1.22 
2 53.88±0.44 50.99±0.68 50.20±0.37 
3 74.58±1.10 67.43±0.49 63.09±0.96 
4 82.35±1.35 80.50±1.77 77.61±0.42 
6 94.28±1.79 89.47±1.35 86.23±1.49 
8 - 97.55±0.21 93.83±0.74 
10 - - - 
12 - - - 
*All values represent mean cumulative percent drug released ± SD (n=3) 
 
 
       Figure 5. Release Profiles of Timolol Maleate from HPMC K15M Matrices 
  
Drug Release from HPMC K100M CR Matrices  
            Low molecular weight HPMC is used predominantly for tablet film coating, while high 
molecular weight HPMC is used as rate-controlling polymer to retard the release of drugs from a 
matrix at levels of 10% to 80% w/w in tablets and capsules (Raymond and Paul, 2003). Results for the 
drug release from HPMC K100M matrices showed in Table 19 and Figure 6. Formulations containing 
HPMC K100M (F4 to F6) have shown initial burst release and extended the release for 8 to 12h. As 
the drug polymer ratio increased to 1:2 (F6), the kinetics of release decreased (98.97% at 12h). The 
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drug release was slower from matrices containing HPMC K100M compared to HPMC K15M. This 
may be due to structural reorganization of HPMC. Increase in concentration and viscosity of HPMC 
may result in increase in the tortuosity or gel strength of the polymer. When HPMC is exposed to 
aqueous medium, it undergoes rapid hydration and chain relaxation to form viscous gelatinous layer 
(gel layer). Failure to generate a uniform and coherent gel may cause rapid drug release (Basak et al., 
2006). 
          Similar findings were reported by Amelia and Vikram, 2007 and Basak et al, 2006. 
They revealed that 30-40% HPMC K100M was able to extend the release of water soluble drugs for 
more than 8 h. 
Table19 : In -Vitro Release Data of Timolol Maleate from HPMC K100M Matrices 
 
Time (hours) F4 F5 F6 
1 37.23±0.97 35.38±1.47 35.16±1.32 
2 51.72±1.68 50.46±0.83 50.08±1.27 
3 71.58±0.87 69.17±0.65 67.58±0.94 
4 80.71±0.54 78.32±0.87 77.73±1.57 
6 89.43±1.63 86.87±0.42 83.83±0.59 
8 97.29±0.53 94.55±0.74 90.87±1.79 
10 - 98.25±1.62 96.14±1.05 
12 - - - 
*All values represent mean cumulative percent drug released ± SD (n=3) 
 
 
Figure 6. Release Profiles of Timolol Maleate from HPMC K100M Matrices 
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Drug Release from Ethylcellulose Matrices  
            Hydrophobic ethylcellulose can be used as a matrix former for the formulation of sustained-
release dosage forms. Batches containing ethylcellulose (F7 to F9) as release retardant, extended the 
release up to 8 -10 hours with initial burst release. As drug polymer ratio increased, the release rate 
was decreased. During dissolution the erosion was observed. The results were shown in Table20  and 
Figure 7.         
 
Table 20: In-Vitro Release Data of Timolol Maleate from Ethylcellulose Matrices 
 
Time (hours) F7 F8 F9 
1 42.27±0.57 38.7±0.82 35.62±0.71 
2 52.47±0.67 47.28±0.69 46.34±0.54 
3 64.86±0.73 59.73±0.87 56.84±0.37 
4 77.27±0.84 74.95±0.31 72.92±0.84 
6 86.63±0.79 81.62±0.64 79.72±0.53 
8 98.31±0.52 96.59±0.63 94.56±0.83 
10 - - - 
12 - - - 
*All values represent mean cumulative percent drug released ± SD (n=3) 
 
 
 
Figure 7. Release Profiles of Timolol Maleate from Ethylcellulose Matrices 
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Drug Release from Combination of HPMC K100M and EC Matrices  
 
               Batches containing combination of HPMC K100M and ethylcellulose (F10 to F12) have 
shown better release profiles (Table 21 and Figure 8). There was no burst release observed with 
formulations F10 to F11, and release was extended up to 10 to 12 hours. As the ethylcellulose 
concentration increases the drug release was decreased further in formulations F12. They prolonged 
the release for 8 hours only. Batch F11 was found to be optimum, as it shown similar release pattern 
as that of theoretical release profile. 
Table 21: In -Vitro Release Data of Timolol Maleate from Tablets Containing HPMC K100M 
CR and Ethylcellulose 
Time (hours) F10 F11 F12 
1 28.73±0.97 25.38±1.54 31.86±1.37 
2 42.24±0.89 35.09±1.65 44.35±1.52 
3 55.85±1.17 51.93±1.69 59.83±1.46 
4 66.38±1.42 62.15±1.99 70.82±1.04 
6 83.35±1.73 73.88±2.01 87.43±1.96 
8 90.10±1.92 81.09±2.92 94.64±1.09 
10 98.43±2.05 87.04±2.48 - 
12 - 97.21±2.59 - 
*All values represent mean cumulative percent drug released ± SD (n=3) 
 
 
 Fig. 8. Release Profiles of Timolol Maleate from Tablets Containing HPMC K100M CR and 
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         Out of total 12 batches, the drug release was extended up to 12 hours for the formulations F6 
and F11. So, these two formulations selected for further studies like kinetic data analysis and 
similarity factor analysis. 
 
Kinetic analysis of dissolution data 
          The release rate kinetic data for the F6 and F11 is shown in Table 30 and Table 31 respectively. 
As shown in Figures 14-18, drug release data was best explained by first order equation, as the plots 
showed the highest linearity (r2 = 0.9955), followed by Hixson-Crowell (r2 = 0.9800) and Higuchi’s 
equation (r2 = 0.9661). As the drug release was best fitted in first order kinetics, indicating that the 
rate of drug release is concentration dependent. Higuchi’s kinetics explains why the drug diffuses at a 
comparatively slower rate as the distance for diffusion increases. The applicability of the formulation 
to the Hixson –Crowell cube root law indicated a change in surface area and diameter of the tablets 
with the progressive dissolution of the matrix as a function of time. 
Mechanism of drug release 
                As shown in Figure 12, the corresponding plot (log cumulative percent drug release vs time) 
for the Korsmeyer-Peppas equation indicated a good linearity (r2 = 0.9741). The diffusion exponent n 
was 0.66, which appears to indicating a coupling of the diffusion and erosion mechanism (Anomalous 
diffusion) and may indicate that the drug release was controlled by more than one process. 
        
Table 22 : Drug Release Kinetics of Batch (F6) Matrix Tablets 
 
Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas 
r2 K0 (h-1) r2 K1 (h-1) r2 KH  (h-1/2 ) r2 KHC (h- 1/ 
3) 
r2 n KKP (h-n) 
 
0.8461 
5.188 0.8665 0.1890 0.933
5 
24.877 0.9695 0.2461 0.9911 0.5
6 
0.4283 
*  r2 = Correlation coefficient; K = Kinetic constant; n= Diffusional exponent. 
 
Table 23 : Drug Release Kinetics of Optimized (F11) Matrix Tablets 
 
Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas 
r2 K0 (h-1) r2 K1 (h-1) r2 KH  (h-1/2 ) r2 KHC (h- 1/ 
3) 
r2 n KKP (h-n) 
 
0.8985 
5.881 0.9955 0.2012 0.966
1 
27.839 0.9800 0.1997 0.9741 0.6
6 
0.3238 
*  r2 = Correlation coefficient; K = Kinetic constant; n= Diffusional exponent. 
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              Figure 9. Zero Order Graph of Optimized Formulation (F11) 
 
             Figure 10. First Order Graph of Optimized Formulation (F11) 
 
 
 
 
 
 
 
 
 
 
                          Figure 11. Higuchi Plot of Optimized Formulation (F11) 
y = -0.0874x + 1.9525
R2 = 0.9955
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 5 10 15
Time (hours)
lo
g 
cu
m
ul
at
iv
e 
of
 %
 d
ru
g
re
m
ai
ni
ng
y = 5.881x + 29.943
R2 = 0.8985
0
20
40
60
80
100
120
0 5 10 15
Time (hours)
Cu
m
ul
at
iv
e 
%
 D
ru
g 
Re
le
as
e
y = 27.839x + 1.051
R2 = 0.9661
0
20
40
60
80
100
120
0 1 2 3 4
SQRT Time
C
um
ul
at
iv
e 
%
 D
ru
g 
R
el
ea
se
d
 
 
K . K  C o l l e g e  o f  P h a r m a c y  Page 56 
 
 
 
 
              Figure 12. Korsmeyer-Peppas Graph of Optimized Formulation (F11) 
 
         
 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 13.  Hixson-Crowell Plot of Optimized Formulation (F11) 
 
Similarity factor analysis 
               
          Similarity factor results for the batches F6 and F11 were given in Table .  Similarity factor 
analysis between F11 tablets and theoretical release has shown an f2 factor greater than 50 at each 
time point with an average value of f2 factor 80.18. Incase of F6 tablets, an average value of f2 factor 
was greater than 50, but at the 3rd and 4th hours f2 factor was less than 50. 
 
          The in-vitro release behaviour of F6, F11 batches of tablets were compared with the theoretical 
release profile. A close relationship was observed between F11 formulation and theoretical release 
patterns, compared to a relationship between F6 and theoretical release patterns (Figure 14). 
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          So, F11 was considered as optimized formulation, as these tablets did not show any burst 
release and extended the release for 12 hours with similar release pattern to that of theoretical release 
profile. 
 
Table 24 : Similarity Factor Analysis 
 
                                           Average % Drug Release                                  f2  factor     
Time (hrs) Theoretical 
release 
F6 F11 F6 F11* 
1 26.16 34.93 25.38 73.03 99.09 
2 33.08 49.86 35.09 59.62 95.05 
3 40.00 66.97 51.93 49.47 66.77 
4 46.92 76.82 62.15 47.25 61.66 
6 60.76 81.87 73.88 64.79 64.79 
8 74.60 89.89 81.09 54.73 78.84 
10 88.44 93.07 87.04 61.58 97.31 
12 99.00 98.07 97.21 66.72 77.99 
* Average value of f2 factor   = 80.18 
 
 
                      Figure 14. Comparative In-Vitro Drug Release Profile  
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                     Swelling and erosion behaviour, FTIR studies, and stability study were performed on 
optimized formulation (F11). 
                          
  Determination of swelling and eroding behaviour 
 
             Since the rate of swelling and erosion is related and may affect the mechanism and kinetics of 
drug release, the penetration of the dissolution medium and the erosion of the hydrated tablets were 
determined. Simultaneously with the swelling study, the percentage erosion of polymer was 
determined. The percentage swelling and erosion of optimized tablet was shown in Figures 15 and 16, 
and data was given in Table 25. Maximum swelling was observed in first 2 hours and gradually it was 
decreased with simultaneous erosion of polymer. 
     Table 25 : Swelling and Erosion Study of Optimized Formulation (F11) 
 
Time (hours) % Swelling % Erosion 
1 76.43 18.72 
2 128.35 24.37 
3 84.57 28.73 
4 71.94 42.62 
6 60.64 56.83 
8 49.53 64.52 
10 36.72 72.41 
12 24.83 93.29 
 
 
 
 
 
 
 
 
 
 
                              
                  
 
Figure 15. Swelling Study of Optimized Formulation (F11) 
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                      Figure 16. Erosion Study of Optimized Formulation (F11) 
 
Fourier transform infrared spectroscopy (FTIR) 
           FTIR spectra of the drug and the optimized formulation were recorded in range of 4000-400 
cm-1. Timolol maleate showed some prominent and characteristic peaks. The peaks at 3305 and 1120 
cm-1 were due to stretching vibrations of O-H and C-O bond of secondary alcohol respectively. Peaks 
at 2967, 2856, and 1707 cm-1 could be assigned to  the asymmetric C-H stretching of CH3 group, 
symmetric C-H stretching of CH2 group, and C=N stretching respectively.  In the optimized 
formulation, the presence of all the characteristic peaks of the Timolol maleate indicates that no 
interaction was occurred between the drug and the excipients. 
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FTIR spectrum of Timolol Maleate 
 
 
FTIR Spectrum of optimized formulation 
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Stability studies 
              Stability studies of the optimized formulation did not reveal any degradation of the drug and 
there was no significant change in the physical properties, drug content, and in vitro release profiles of 
the optimized formulation after storage for 3 months. 
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SUMMARY & CONCLUSION 
 
Matrix tablets were compressed without any problem and do not require any change in ratio 
of excipients in formulation. Results of the present study demonstrated that combination of 
both hydrophilic and hydrophobic polymers could be successfully employed for 
formulating sustained-release matrix tablets of Timolol maleate. All the formulations 
containing drug to polymer ratio 1:1.5 and MCC as a diluent extended the drug release for 8 
to 12 hours. The drug release rate was slower with the tablets containing combination of 
both hydrophilic HPMC K100M and hydrophobic EC polymers. Wet granulation method 
was found to be better choice to extend the drug release for 12 hours.Majority of 
formulations have released the drug by non-Fickian diffusion. 
 
For formulation F1 to F3 HPMC K15M was used as polymer in a ratio of Drug to polymer 
as 1:0.5, 1:1, 1:1.5. Formulation F1 composed of drug polymer ratio of 1:0.5, failed to 
sustain release beyond 6h. This formulation underwent erosion before complete swelling 
could take place. Formulations with drug polymer ratios 1:1 (F2), 1:1.5 (F3) have extended 
the drug release for 8h. All these formulations have shown more than 30% release in the 
first 1 hour indicating burst release. 
 
For formulation F4 to F6 HPMC K100M was used as polymer in a ratio of Drug to polymer 
as 1:0.5, 1:1, 1:1.5. Formulations containing HPMC K100M (F4 to F6) have shown initial 
burst release and extended the release for 8 to 12h. As the drug polymer ratio increased to 
1:2 (F6), the kinetics of release decreased (98.97% at 12h). The drug release was slower 
from matrices containing HPMC K100M compared to HPMC K15M. 
 
For formulation F7 to F9 Ethylcellulose was used as polymer in a ratio of Drug to polymer 
as 1:0.5, 1:1, 1:1.5. Batches containing ethylcellulose (F7 to F9) as release retardant, 
extended the release up to 8 -10 hours with initial burst release. As drug polymer ratio 
increased, the release rate was decreased. During dissolution the erosion was observed. 
 
 For formulation F10 to F12 HPMC K100M and Ethylcellulose was used as polymer in a 
ratio of Drug to polymer as 1:0.5, 1:1, 1:1.5. Batches containing combination of HPMC 
K100M and ethylcellulose (F10 to F12) have shown better release profiles (Table 21 and 
Figure 8). There was no burst release observed with formulations F10 to F11, and release 
was extended up to 10 to 12 hours. As the ethylcellulose concentration increases the drug 
release was decreased further in formulations F12. They prolonged the release for 8 hours 
only.  
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Out of total 12 batches, the drug release was extended up to 12 hours for the formulations 
F6 and F11. So, these two formulations selected for further studies like kinetic data analysis 
and similarity factor analysis.          
The in-vitro release behaviour of F6, F11 batches of tablets were compared with the 
theoretical release profile. A close relationship was observed between F11 formulation and 
theoretical release patterns, compared to a relationship between F6 and theoretical release 
patterns (Figure 14). So, F11 was considered as optimized formulation, as these tablets did 
not show any burst release and extended the release for 12 hours with similar release pattern 
to that of theoretical release profile. 
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CONCLUSION: 
The following conclusions were drawn from these experimental results: 
 
¾ Sustained Release matrix tablets of Timolol maleate were successfully formulated with 
HPMC K 15, HPMC K100M and EC.  
¾ Granules were evaluated for micromeritic properties like bulk density, tapped density, 
carr’s index, Hausners ratio and angle of repose. The granules showed good flowing 
properties. 
¾ All formulations were subjected to dissolution studies. Dissolution was conducted in 
0.1HCL and pH 6.8 phosphate buffer. The release rate of drug is controlled when 
different concentrations of HPMC and EC are used together. 
¾ Optimized formulation F11 (drug to polymer ratio 1:2) which includes both HPMC 
K100M and EC (1:1) has successfully sustained the drug release  for 12 hours and the 
drug release pattern was similar to theoretical release profile.  
¾ The drug release from optimized formulation (F11) followed first-order kinetics 
via non-Fickian (anomalous) diffusion.  
¾ The release process involves anomalous diffusion mechanism or diffusion coupled with 
erosion, as indicated by the n value of 0.66 in Korsmeyer’s plot.  
¾ There was an alteration in the surface area and diameter of the tablets with the progressive 
dissolution of the matrix as a function of time, as indicated in Hixson-Crowell plot. 
¾ FTIR studies combined with stability studies proved the integrity of the developed matrix 
tablets. 
¾  FTIR studies revealed that there was no interaction between the drug and 
excipients. 
¾ Finally the present study concluded that the combination of both hydrophilic and 
hydrophobic polymers could be successfully employed for formulating sustained-release 
matrix tablets of Timolol maleate with a good drug release. 
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